Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Vorinostat (SAHA, MK0683) Chemical Structure

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 220 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 103 Publications

20 Customer Reviews

  • Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

    Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

    J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

    Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

    J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

    IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

    Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m-/-mice were injected s.c. with 1×106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b2)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch, scorrection and a Mann-Whitney U test.

     

     

    Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    (a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Targets
HDAC [1]
(Cell-free assay)
~10 nM
In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A20 NHf2ZVFMcW6jc3WgRZN{[Xl? NVO4[3lQOSCq MnPwSG1UVw>? M3n2d4FvfGlvSFTBR|Eh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNVEzKM7:TR?= NICwdpcyOTl4MES4PS=>
Friend leukemic cell NXLke3dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XxbVUxKM7:TR?= MnvnO|IhcA>? NXnre4NOTE2VTx?= NELneJlKSzVyPUCuPVkh|ryP MYCxNlExQTlzMx?=
K562 M3HYN2tqdmG|ZTDBd5NigQ>? MY[2JIg> MWXEUXNQ M17yS2lvcGmkaYTpc44hd2ZiaIXtZY4hcGm|dH;u[UBl\WGlZYT5cIF{\SBqbXn4eJVz\SCxZjDISGFEOSCjbnSgTGRCSzJrIIfpeIghUUN3MDDv[kAxNjBzIN88US=> NYi5c4R2OTJ2MUmzPFA>
HT1080 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP3b3U5PzJiaB?= MkLuSG1UVw>? MXLJR|UxRTJwNDFOwG0> NEPoeXIyOjJ5MEG3OS=>
H1299 NVzUW29QU2mwYYPlJGF{e2G7 MU[yNEBucW5? M3nOXmROW09? MkDITY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2= MUmxOFUzOTR{Mh?=
H1299 NFLCUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDEO|IhcA>? NYrMO5RSTE2VTx?= MnHXTWM2OD15LkK0JO69VQ>? MWWxOFUzOTR{Mh?=
HeLa M17MOGtqdmG|ZTDBd5NigQ>? Ml\lN|AhdWmw NGPZfI9KdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDobZN1d26nIHTlZYNmfHmuYYPlJJdqfGhiSVO1NEBw\iByLkK4JO69VQ>? M{PoPVE2PjB|OUS5
LOX-IMVI NIXv[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PLe|Q5KGh? NVXxU4hoUUN3ME2xMlMh|ryP NWfSTZpUOTV5MUW0O|A>
NCI-H226 NFnOOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:0PEBp MojaTWM2OD1{Lk[g{txO M3XBUlE2PzF3NEew
RXF-631L Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[0PEBp NGe3VmNKSzVyPUKg{txO M1Tv[VE2PzF3NEew
SNB-78 NITLOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3uOFghcA>? MWTJR|UxRTF4IN88US=> MkC3NVU4OTV2N{C=
St-4 NX;oZ|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Fb|Q5KGh? MV3JR|UxRTVwMjFOwG0> MVexOVcyPTR5MB?=
ARP1 Mn;qSpVv[3Srb36gRZN{[Xl? MXuyJO69VQ>? NHLnbHg3KGh? NX;YTZFvUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v NVe5eGhlOTR5M{S4NFY>
CEM MnnET4lv[XOnIFHzd4F6 NVXTXVduOSCq NX[wW4Z1TE2VTx?= MXPJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{Og{txO MVKxOlQzODB4NB?=
HCT15 NEDNeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7JcmN6PDhiaB?= NGjmWJZIUTVyPUCuPFIh|ryP M{P2SFE3PzJ|MkK3
NCI-H23 NYjGZpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xj[lQ5KGh? NIOzOZBIUTVyPUCuPVIh|ryP NEK2cIEyPjd{M{KyOy=>
GM15850 NWX4eoZRU2mwYYPlJGF{e2G7 NXvoUXBrOi53IN88US=> NXz2fGNRQTZiaB?= MYjEUXNQ Ml24TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEG0JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n MVOxOlkzOTN4Nx?=
GM15850 NYXyfmFWU2mwYYPlJGF{e2G7 NWXVOmtHOi53IN88US=> NE\oeWY6PiCq MofqSG1UVw>? Mn7uTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? NVHYZpZ7OTZ7MkGzOlc>
GM15850 NWXDeJpEU2mwYYPlJGF{e2G7 M2XoWFIvPSEQvF2= NW\iSZVvQTZiaB?= M{LNbWROW09? NWroTnJRUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l M{PFU|E3QTJzM{[3
GM15850 NVvrfIxwU2mwYYPlJGF{e2G7 NFjzcmYzNjVizszN NYj4TYU2QTZiaB?= NW\vclFGTE2VTx?= NHnvNopKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= MXuxOlkzOTN4Nx?=
GM15850 NYPpU4dQU2mwYYPlJGF{e2G7 Ml3uNk42KM7:TR?= NI\Mfpk6PiCq MV7EUXNQ NGLCVZlKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= M{L3WFE3QTJzM{[3
GM15850 MXXLbY5ie2ViQYPzZZk> NUXCfGFzOi53IN88US=> MXK5OkBp MVrEUXNQ NWnVOXRVUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l NVG0ZY1MOTZ7MkGzOlc>
U937 NHLFWHlHfW6ldHnvckBCe3OjeR?= NV[yTFJHPSEQvF2= NHXXbIQzPCCq NHzaSo1FVVOR NITlNZlE\WyuIHP5Z4xmKGG{cnXzeEBjgSCjY3P1cZVt[XSrb36gZZQhWy:JMj;NJJBp[XOn MYmxO|AxPDdzOB?=
H661 M3;6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO0PEBp Mo\VTWM2OD1zIN88US=> NITudVcyPzF3N{CwPS=>
U937 NVrM[JY2TnWwY4Tpc44hSXO|YYm= M3LkOVUh|ryP NGDr[I4zPCCq NY[ycVdNTE2VTx?= NWC2b3lNUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=> NG\kbYQyPzR2N{e1NC=>
U937 M2\ye2Z2dmO2aX;uJGF{e2G7 NXm3Znh6OSEQvF2= NXy1OJk{OjRiaB?= M2D6VGROW09? M2faeWVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u NYPmdJl6OTd2NEe3OVA>
RAW264.7 MoD3SpVv[3Srb36gRZN{[Xl? NW\veI5EOTBizszN NVrid3VuOjSq MWf3ZZRmeg>? Ml\5TY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?= M2TNT|E4PDd5NUG4
RAW264.7 MkLISpVv[3Srb36gRZN{[Xl? MkH1NVAh|ryP MVeyOIg> NFLUfpV4[XSnch?= MnfsTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=> MXixO|Q4PzVzOB?=
SC9 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnNZVJGPDhiaB?= NHPQV2xKSzVyPUCuOlA3KM7:TR?= MkXYNVc2ODd{MUm=
ST14A NH3ndGxHfW6ldHnvckBCe3OjeR?= NEXJbVc2KG6P MXG3NkBp NHLac|JKdmO{ZXHz[UBqdiCURWPUM25TW0ZibWLORUBmgHC{ZYPzbY9v NIDx[moyPzV4NUm5Ny=>
ST14A NF\EUWpHfW6ldHnvckBCe3OjeR?= M{LTNlUhdk1? MWK3NkBp NIfoSG9KdmO{ZXHz[UBqdiCHMl[xJI1TVkFiZYjwdoV{e2mxbh?= MmrJNVc2PjV7OUO=
PANC1 M1HDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrFbGkzOSEQvF2= M1znbWlEPTB;MD60OUDPxE1? NF7NWFEyPzV6OEe0OC=>
PANC1 MmPYSpVv[3Srb36gRZN{[Xl? NVzBOodNOSEQvF2= NVfTRo9lOjRiaB?= MYPJcoNz\WG|ZTDpckBxOjGZQV[xM2NKWDFiZ3Xu[UBmgHC{ZYPzbY9v MlXwNVc2QDh5NES=
PANC1 NUnYfZJzTnWwY4Tpc44hSXO|YYm= NX3Gc|J{OSEQvF2= MmD2NlQhcA>? MmfZTY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36= MVyxO|U5QDd2NB?=
PT45 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jKR2lEPTB;NDFOwG0> MWmxO|U5QDd2NB?=
ACHN NXfoOGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\IRoJjOjFiaB?= NXvjZlJNT0l3ME2wMlY2KM7:TR?= Mn3kNVc3PjJ4ME[=
PC3 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2yNUBp NHz4eVVIUTVyPUCuO|Eh|ryP NXrz[mVWOTd4NkK2NFY>
A431 NFG5NJpEgXSxdH;4bYMhSXO|YYm= NHHNXWM4OiCq MVjJR|UxRTRwMjFOwG0> NILOVJMyPzZ7MUe2Ny=>
Cal27 NV:zWlBrS3m2b4TvfIlkKEG|c3H5 M3rEfVczKGh? MWTJR|UxRTNwMjFOwG0> NWjaXVR6OTd4OUG3OlM>
CCRF-CEM NVXlUlFUS3m2b4TvfIlkKEG|c3H5 NEWwfmo4OiCq M4TmO2lEPTB;MD64JO69VQ>? MlrSNVc3QTF5NkO=
EOL1 M{TpVmN6fG:2b4jpZ{BCe3OjeR?= MmPYO|IhcA>? M{XHPWlEPTB;MTFOwG0> MUixO|Y6OTd4Mx?=
Hec-1-A NHq5WWdEgXSxdH;4bYMhSXO|YYm= MYO3NkBp NI\IT3NKSzVyPUGg{txO NVPs[Ih5OTd4OUG3OlM>
HeLa NWDxUIt[U2mwYYPlJGF{e2G7 Ml\YNVAh|ryP NV\aW29pOzBibXnu MnrySG1UVw>? NG\X[4pKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=> M3jSRlE4PjlzN{[z
RKOp21 NGnMWYxEgXSxdH;4bYMhSXO|YYm= MnjHO|IhcA>? Mlr0TWM2OD1zLke2JO69VQ>? M1XhTVE4PjlzN{[z
Saos2 NGnvbJdEgXSxdH;4bYMhSXO|YYm= MUm3NkBp MVLJR|UxRTJwMzFOwG0> NEn5WnMyPzZ7MUe2Ny=>
SK-OV-3 NILxUnBEgXSxdH;4bYMhSXO|YYm= MXq3NkBp NFvkOlZKSzVyPUKuNkDPxE1? MkfMNVc3QTF5NkO=
U87MG MXvDfZRwfG:6aXOgRZN{[Xl? NGHXbFg4OiCq M1nJRmlEPTB;MUGg{txO NH:xOYUyPzZ7MUe2Ny=>
NUGC3 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[1JO69VQ>? NUjaO3o6OjRiaB?= MY\HTVUxRTJwN{mg{txO NH\Kdo8yPzlyNEi0Ny=>
CCD1059SK MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj6fG9SUUN3ME20N{42KM7:TR?= MoHHNVgzPDd3NUS=
HepG2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfFOHN7UUN3ME2wMlAxODZizszN NHjSR4gyQDJ2N{W1OC=>
HT1080 NXn2[3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW1N485UUN3ME2wMlAxOjRizszN NHrLZmoyQDJ2N{W1OC=>
SKBR3 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfNVmVKSzVyPUCuPEDPxE1? MX6xPFI1PzV3NB?=
SNB78 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TtbGVEPTB;MU[g{txO NWexbY1NOTh{NEe1OVQ>
SQ20B M1XZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO2TWM2OD1|IN88US=> M1G0XFE5OjR5NUW0
St4 NHv2bIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PrVWVEPTB;NT6yJO69VQ>? NF[y[YcyQDJ2N{W1OC=>
MCF7 MoOzSpVv[3Srb36gRZN{[Xl? M2TsTlExKM7:TR?= MoLsPEBp MmTPSG1UVw>? M2\vUmlv\HWldHnvckBw\iC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44> M2LuZ|E5OjZ7MkK2
HEK293 M17tSGtqdmG|ZTDBd5NigQ>? NEnVSJMyKGh? Mo\TSG1UVw>? NXvnbFBGUW6qaXLpeIlwdiCxZjDISGFEOSC5aYToJGlEPTBib3[gNE4xOyEQvF2= MWOxPFMxQDV4Mx?=
HEK293 M3ntXWtqdmG|ZTDBd5NigQ>? MYqxJIg> NXnGfW1lTE2VTx?= M4PCPWlvcGmkaYTpc44hd2ZiSFTBR|Mhf2m2aDDJR|UxKG:oIECuNFU4KM7:TR?= MlW4NVg{ODh3NkO=
G401 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XF[|czKGh? NF;ORXJFVVOR M{T4VWlEPTB;MTFOwG0> MlTBNVg{PzB|N{O=
HeLa MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f1bVczKGh? MnTVSG1UVw>? NUG2WodYUUN3ME2wMlQ3KM7:TR?= MnfJNVg{PzB|N{O=
Human renal epithelial cell MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKzU4h6PzJiaB?= NGrGO|ZFVVOR MWjJR|UxRTF2IN88US=> MWGxPFM4ODN5Mx?=
U937 NX7RU3B5TnWwY4Tpc44hSXO|YYm= Mlm2OUDPxE1? MmrFNlQhcA>? M4fu[2lv\HWldHnvckBw\iCqaYP0c45mKEh2IHj5dIVz[WOndInsZZRqd25? MUKxPFM5OTJ|OB?=
U937 NWDtfldRTnWwY4Tpc44hSXO|YYm= MXy1JO69VQ>? M3PuZVI1KGh? NEjXXppKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u NFfzSJQyQDN6MUKzPC=>
U937 MX7GeY5kfGmxbjDBd5NigQ>? MW[1JO69VQ>? MoPFNlQhcA>? M3q1Umlv\HWldHnvckBw\iCyMkGg[ZhxemW|c3nvci=> Ml3XNVg{QDF{M{i=
U937 NXPNVINqTnWwY4Tpc44hSXO|YYm= MYq1JO69VQ>? MmDPNlQhcA>? NIS5[IVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| MUGxPFM5OTJ|OB?=
U937 MoW3SpVv[3Srb36gRZN{[Xl? MnnJOUDPxE1? MofJNlQhcA>? MknVTY5lfWO2aX;uJI9nKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25? M1;WXFE5OzhzMkO4
U937 MULLbY5ie2ViQYPzZZk> M{PSVVUh|ryP NF3Td5EzPCCq M{HRemlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{G= M4DBfVE5OzhzMkO4
U937 MWHLbY5ie2ViQYPzZZk> NITybpM2KM7:TR?= MVmyOEBp MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2 NUn1[lVqOTh|OEGyN|g>
HEK-TE M2HY[GZ2dmO2aX;uJGF{e2G7 NH\XbW82KM7:TR?= M4\KblZp MVPEUXNQ NU\mO21QUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=> NGPFfoYyQDR|NEG0OC=>
HPDE6c7 NV[0O4dLS3m2b4TvfIlkKEG|c3H5 MVW1NEDPxE1? NUXIUmViPzJiaB?= NIGwRoFFVVOR NFzIeZVKSzVyPUGuN{DPxE1? M3f1c|E5PDl2NE[z
Human microvascular epithelial cell NIm0eoNEgXSxdH;4bYMhSXO|YYm= NFe0Olk2OCEQvF2= MlTQO|IhcA>? MlnNSG1UVw>? M4foZ2lEPTB;MT6zJO69VQ>? MW[xPFQ6PDR4Mx?=
Hup T3 NWnPWG5ZS3m2b4TvfIlkKEG|c3H5 MVO1NEDPxE1? NEL3c5A4Omh? M1vz[mROW09? NHrjdphKSzVyPUCuPEDPxE1? M3HiUVE5PDl2NE[z
Mia Paca2 NWH4XXd1S3m2b4TvfIlkKEG|c3H5 NYDBTI1{PTBizszN Mn[5O|Jp NXPJWJdvTE2VTx?= MVTJR|UxRTFwMTFOwG0> Mo\xNVg1QTR2NkO=
Panc 04.03 NYfIeJd3S3m2b4TvfIlkKEG|c3H5 MXW1NEDPxE1? M{[4TlczcA>? M{P4OGROW09? NEHJbmRKSzVyPUGuNkDPxE1? NWf6RZFuOTh2OUS0OlM>
SU 86.86 MVPDfZRwfG:6aXOgRZN{[Xl? NYLNcotiPTBizszN NFToNZg4Omh? MWHEUXNQ NV\KfIQ2UUN3ME2xMlMh|ryP M1[1[lE5PDl2NE[z
HEK293 MXPLbY5ie2ViQYPzZZk> NH7SPZo{KGh? MYHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=> M{m1UlE5PTV6Nk[5
HeLa MXLLbY5ie2ViQYPzZZk> MkP1NkBp MYTJcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO M2PoSlE5PTV6Nk[5
RAW264.7 MVPGeY5kfGmxbjDBd5NigQ>? MlOzNkDPxE1? M{G4dVMvPSCq MYrEUXNQ NGDWSlNCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gbY5n\WO2ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO M4TybVE5PjR2OU[5
NB4 M1PGT|Q5cA>? MWjEUXNQ NEHZXVNKSzVyPUCuOkDPxE1? MkPHNVg4OjN|NEm=
HEK293 MXfGeY5kfGmxbjDBd5NigQ>? M3G2PVExKM7:TR?= M3:0c|I1KGh? M4[3emROW09? MmXqRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR|YTDzbYdv[Wyrbneg[ZhxemW|c3Xk MVixPVAzOjZ5NR?=
HCT116 M{nDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO3Nog> NYDIZ|VKTE2VTx?= NWHtbIx[UUN3ME2wMlMyKM7:TR?= Ml7rNVkxQDR{OUS=
HeLa MXnLbY5ie2ViQYPzZZk> NYXleHlNOiEQvF2= MWKzNEBucW5? M33zZmROW09? M3TYTGlvcGmkaYTpc44hd2ZiSFTBR|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?= NEjybnUyQTB6NEK5OC=>
IGROV1 NFPhOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTZO|IhcA>? MV;EUXNQ MWTJR|UxRTJwMjFOwG0> MYWxPVA5PDJ7NB?=
IGROV1 MoDBT4lv[XOnIFHzd4F6 NGHYZZY2KM7:TR?= M4fC[VI1KGh? MXrEUXNQ NFfhe5BKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNicEWzJIFk\XS7bHH0bY9v NH\jbWMyQTB6NEK5OC=>
IGROV1 MW\LbY5ie2ViQYPzZZk> NVrZVpU6OTBizszN NVy4dGlwPCCq M1LoRmROW09? MUjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcGm|dH;u[U1JPCCjY3X0fYxifGmxbh?= MmrmNVkxQDR{OUS=
IGROV1 NUXjR2VSU2mwYYPlJGF{e2G7 Ml3aNVAh|ryP M2rTV|QhcA>? NFS0eHdFVVOR MkPMTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9v NEG1Z28yQTB6NEK5OC=>
T24 M1nCZmtqdmG|ZTDBd5NigQ>? MUSzJIg> NXXyWGdHUW6mdXP0bY9vKG:oIHjpd5RwdmViSEOgZYNmfHmuYYTpc44hf2m2aDDFR|UxKG:oIECuNVIh|ryP NX;Fb3gzOTlyOESzPVU>
T24 Mln5T4lv[XOnIFHzd4F6 MVezJIg> M1;sSWlv\HWldHnvckBw\iCjbIDoZUB1fWK3bHnuJIFk\XS7bHH0bY9vKHerdHigSWM2OCCxZjCwMlI2KM7:TR?= NIXUN4QyQTB6NEO5OS=>
HeLa NYiwfWF4U2mwYYPlJGF{e2G7 NWPNOY92OTVibXnu NH3yfVBFVVOR M1j3TmlvcGmkaYTpc44hd2ZiSFTBR|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0> Mnq2NVkxQTN6OES=
HeLa MW\LbY5ie2ViQYPzZZk> NGLwZoMyPSCvaX6= M1PFT2ROW09? Mlm0TY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2= NUPXNYF[OTlyOUO4PFQ>
NCI-H69 MVnDfZRwfG:6aXOgRZN{[Xl? NEHMRW04OiCq M1zXfGROW09? MmroTWM2OD1{LkC2JO69VQ>? Mk\3NVkxQTN6OES=
SKMES1 MXnDfZRwfG:6aXOgRZN{[Xl? MUO3NkBp NYfLZ4hDTE2VTx?= NHfQOZhKSzVyPUKuOFIh|ryP NGXTU20yQTB7M{i4OC=>
S2 NYfwZ4VwU2mwYYPlJGF{e2G7 MoHZNE4yNTFyIN88US=> NInibI4yKGh? MnHETY5pcWKrdHnvckBw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gTGRCSzFiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB3OTFOwG0> M2mxTlE6OzF5NEWw
SHSY5Y NXvHT|NOU2mwYYPlJGF{e2G7 MVSxNEDPxE1? NWm1OmpJPDhiaB?= M{DiWmROW09? NHK5PFdKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOUDPxE1? M1;SXVE6OzR2MUe1
SHSY5Y MYnDfZRwfG:6aXOgRZN{[Xl? MUmxNEDPxE1? M13McVQ5KGh? MnL3SG1UVw>? Moi0TWM2OD1{IN88US=> M2nzSVE6OzR2MUe1
DMS114 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOyNGpbPDhiaB?= NULCb2RCT0l3ME2yMlkh|ryP Ml2xNVk1OTl{MEW=
HBC5 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17PcFQ5KGh? NUDVWWVQT0l3ME2xO{DPxE1? MmLJNVk1OTl{MEW=
SNB78 M3vaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm0PEBp MYPHTVUxRTF4IN88US=> NEjHTGYyQTRzOUKwOS=>
HeLa MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfyO|IhcA>? MVPEUXNQ NXHqVGp1UUN3ME2wMlQ3KM7:TR?= M4joZlE6PDRzOES2
BHK MnyxT4lv[XOnIFHzd4F6 NEPtU4k2KM7:TR?= M3u2dVI1KGh? NEjGdZlFVVOR M3nDZmlvcGmkaYTpc44hd2ZiSFTBR|ch\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv MkjVNVk6PjZ5OEm=
CFBE41o- NYKx[I4{U2mwYYPlJGF{e2G7 MUe1JO69VQ>? NXv4fVNLQCCq M4W2SWROW09? NIO4clZKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaInw[ZJi[2W2eXzheIlwdiCxZjDobZN1d26nIFiz NX7tdpV7OTl7Nk[3PFk>
CFBE41o- MonIT4lv[XOnIFHzd4F6 NULOUoVEPSEQvF2= MorzOEBp NE\XWZRFVVOR M3LSV2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBt\X[nbB?= NIrTUJcyQTl4Nke4PS=>
CFBE41o- MVHLbY5ie2ViQYPzZZk> Mmf6NUDPxE1? NX;PPVFQOSCq NX3KdnMxTE2VTx?= NGfvWJVKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gR2ZVWiCycn;0[YlvKGyndnXs NIr6R5kyQTl4Nke4PS=>
Primary bronchial epithelial cell NFrRbm1McW6jc3WgRZN{[Xl? NHKyNGIyKM7:TR?= MYiyOEBp NYnhTWdKTE2VTx?= NFzzUoRKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25? MXGxPVk3Pjd6OR?=
CFBE41o- MVXLbY5ie2ViQYPzZZk> NEf4TIsyKM7:TR?= MoHEOUBl[Xm| MUPEUXNQ MlfJTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrenH0bY9vKG:oIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4> NXfCdoc3OTl7Nk[3PFk>
CFBE41o- MoDwT4lv[XOnIFHzd4F6 NXjHTYRwOSEQvF2= NF64doMzPCCq M3:5bmROW09? M3vRfGlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSoRmdHSjNUC4JGNHXFJicILveIVqdiC2cnHm[olkc2mwZx?= M{f0VlE6QTZ4N{i5
CFBE41o- NHXDWHpMcW6jc3WgRZN{[Xl? MYe1JO69VQ>? NEO4TWkzPCCq MnrUSG1UVw>? Ml;nTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1? M2WzW|E6QTZ4N{i5
CFBE41o- M1;PfWtqdmG|ZTDBd5NigQ>? MVy1JO69VQ>? NGLjVmczPCCq Ml;TSG1UVw>? NHXYd2xKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu NWDpXG12OTl7Nk[3PFk>
CFBE41o- MlrhT4lv[XOnIFHzd4F6 MVy1JO69VQ>? NHXrfWQzPCCq NUi2UpJKTE2VTx?= MVPJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGOxcoLlZ5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn2= M3TtfFE6QTZ4N{i5
Primary bronchial epithelial cell MXHLbY5ie2ViQYPzZZk> NE[3RVg2KM7:TR?= NUXRZY1tOjRiaB?= MnPiSG1UVw>? M4DpfmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v M4LjOFE6QTZ4N{i5
Primary bronchial epithelial cell NUHOVIdiU2mwYYPlJGF{e2G7 M4XUUVEh|ryP M3nTN|k3KGh? MmD3SG1UVw>? MYHJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM> NX3DUoFLOTl7Nk[3PFk>
BxPC3 M4\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq3NkBp M4DuUWlEPTB;Mj63JO69VQ>? NVqzW2l1OjBzNEO3O|g>
CAL27 NGrIeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVm3NkBp NH\RcpRKSzVyPUOuO|Ih|ryP MXSyNFE1Ozd5OB?=
Capan1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnrbYM4OiCq M3\RUmlEPTB;Nz6zJO69VQ>? M{K3OFIxOTR|N{e4
HCC827 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jzW|czKGh? MoPjTWM2OD1zLkig{txO NFWzcI8zODF2M{e3PC=>
LNCAP Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf1O|IhcA>? MWnJR|UxRTBwNUig{txO MYSyNFE1Ozd5OB?=
NCI-H2122 NHXONXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fFT|czKGh? MlfmTWM2OD15LkWg{txO NHKxdFUzODF2M{e3PC=>
NCI-H358 NWXvWIZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULBeJQyPzJiaB?= NXXyVXRKUUN3ME2yMlUh|ryP Ml3oNlAyPDN5N{i=
SCC15 M2PZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKyTYxxPzJiaB?= MVPJR|UxRTJwNEmg{txO MYeyNFE1Ozd5OB?=
SCC25 NX\qTlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXTO|IhcA>? NIfTVFVKSzVyPUGuPVMh|ryP NGHp[GQzODF2M{e3PC=>
SKHEP1 NGTqdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\K[FczKGh? Mk\PTWM2OD1|LkS2JO69VQ>? NIHYUWszODF2M{e3PC=>
BJ Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNFAh|ryP NFXhe3M1QCCq NYL4S|BbTE2VTx?= M3jPWWdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN NV;5PWxnOjBzNEO4OFA>
MUF MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrjVnM4OTByIN88US=> M2jyT|Q5KGh? MW\EUXNQ MlGwS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2= NYq1cGROOjBzNEO4OFA>
Caco-2 NELzepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPLTVAyODBizszN NXPkbFhHPDiq NH;mXHdFVVOR NITtemRKSzVyPUiuNUDPxE1? NV;McYF2OjBzNEO4OFA>
Caco-2 MXnLbY5ie2ViQYPzZZk> NGTxO2Q2KM7:TR?= NXnhZnVrPCCq MkSzSG1UVw>? NEjBbW9KdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9vKEmFNUCgc4YhOC5yM{eg{txO NF\pTGozODF2M{i0NC=>
Caco-2 NHzrUZNMcW6jc3WgRZN{[Xl? NYT4dYJPOC5|MU[gcm0hfG9iM{GuOkDPxE1? NIT2NWw1KGh? MoTOSG1UVw>? MVvFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzFid3n0bEBKSzVyIH;mJFAvOTF7IN88US=> MmnuNlAyPDN6NEC=
Caco-2 NFzhbFRMcW6jc3WgRZN{[Xl? NETCcoMxNjNzNjDuUUB1dyB|MT62JO69VQ>? NGnrXow1KGh? MUfEUXNQ MWrFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzNid3n0bEBKSzVyIH;mJFAvOTR5IN88US=> NWCwZZBPOjBzNEO4OFA>
Caco-2 NVfpeHZ1U2mwYYPlJGF{e2G7 MlzNOk4{OiCwTTD0c{A3OzJizszN NHfs[m41KGh? MXLEUXNQ NV7NVVg{TXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO1JJdqfGhiSVO1NEBw\iBzMj62JO69VQ>? M4\pVlIxOTR|OESw
Caco-2 MWnLbY5ie2ViQYPzZZk> MV62MlMzKG6PIITvJFY{OiEQvF2= MW[0JIg> NILnVW9FVVOR NUPHfnZNTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO3JJdqfGhiSVO1NEBw\iB2MTFOwG0> NX3vNZZ[OjBzNEO4OFA>
Caco-2 MlPDT4lv[XOnIFHzd4F6 NX7iUFc{OC5|MU[gcm0hfG9iM{GuOkDPxE1? NFHyS4M1KGh? MlXtSG1UVw>? NHXifYFGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{[= MoDRNlAyPDN6NEC=
HepG2 MVrLbY5ie2ViQYPzZZk> M4H6fFUh|ryP M2\0TlZp M2ewN2ROW09? NUS5[Iw5UW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm|dH;u[UBi[2W2eXzheIlwdg>? MU[yNFE1Ozh2MB?=
HepG2 M3;neGtqdmG|ZTDBd5NigQ>? NXruXYZrPSEQvF2= NF\nelE3cA>? NVT5bpZUTE2VTx?= NE\h[HRKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIh6eGW{YXPleJlt[XSrb36= M{OxTlIxOTR|OESw
HepG2 MUfLbY5ie2ViQYPzZZk> NIHDV4g2KM7:TR?= NXfyeHV3Pmh? NGC0U2JFVVOR MV3JcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w MWKyNFE1Ozh2MB?=
HepG2 Mmn5T4lv[XOnIFHzd4F6 NWXtZ2RiPSEQvF2= M1;URlZp NFnCSGJFVVOR MVTJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDIN{9JPCCqaYP0c45mKGGlZYT5cIF1cW:w Mn3RNlAyPDN6NEC=
COLO205 NUPobndwU2mwYYPlJGF{e2G7 MkT2NVAh|ryP M3HLZVI1KGh? MoHQSG1UVw>? MVPJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh|ryP NI\xXIIzODR3MUO3PC=>
SCC4 MmrET4lv[XOnIFHzd4F6 M4HS[FEh|ryP NEHOOZEzPGh? MkTjTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36= MYKyNFQ2OjJ{NR?=
SCC4 Ml;nT4lv[XOnIFHzd4F6 NVjG[o1TOSEQvF2= NVXBeog{OjSq MmPtTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViYXPleJlt[XSrb36= NH;VcnUzODR3MkKyOS=>
SCC4 NGC1RVlHfW6ldHnvckBCe3OjeR?= NITtXo0yKM7:TR?= MkfyOUBucW5? NHrxXZBC\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO|aX;u NGO2TVMzODR3MkKyOS=>
NB4 MmjGSpVv[3Srb36gRZN{[Xl? Mn7QOUDPxE1? M1S5O|I1KGh? M1\s[2ROW09? MWHD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn M1u3[|IxPDlzNESw
NB4 NESzelVMcW6jc3WgRZN{[Xl? MnjrOUDPxE1? MX6yOEBp MXrEUXNQ MonQTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHHj[ZR6dGG2ZTD0eYJ2dGmwIHzleoVt MnLBNlA1QTF2NEC=
NB4 NXK3W2l7TnWwY4Tpc44hSXO|YYm= NILxbI02KM7:TR?= M3jobVI1KGh? NVy5SG5KTE2VTx?= NX3DU|VJUW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v MVeyNFQ6OTR2MB?=
NB4 NEXZNFJMcW6jc3WgRZN{[Xl? M4[5fVUh|ryP NF;BdFczPCCq M1r2c2ROW09? Mm\HTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgZYNmfHmuYYTpc44> NIPvTXkzODR7MUS0NC=>
NUGC3 NGfnOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnPS2k2OD1{Lkm0JO69VQ>? NY\BRnQzOjB6NUC5O|E>
A549 NUjyZ|dkTnWwY4Tpc44hSXO|YYm= M1jEW|Uh|ryP NEnSSVE{KGh? M3nUdGROW09? M2n2eGlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> Mny5NlA5PTV{MEi=
HUT78 M1P1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILzbFY4OiCq MXrEUXNQ Mn3qS2k2OD1yLkOg{txO NFLM[IUzODh6NEKwPC=>
U937 NW\1W5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\DPWlZPzJiaB?= M3L4d2ROW09? NYPsSYFQT0l3ME2wMlM6KM7:TR?= M{OweVIxQDh2MkC4
A431 MX\DfZRwfG:6aXOgRZN{[Xl? MkTaO|IhcA>? MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR|UxKG:oIESuNkDPxE1? MUiyNVA5ODZ{OR?=
A549 M4PzRWN6fG:2b4jpZ{BCe3OjeR?= MYG3NkBp Mn7pR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlgh|ryP MoH3NlExQDB4Mkm=
CAL27 MnG2R5l1d3SxeHnjJGF{e2G7 MXe3NkBp M{DoOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNCVDJ5IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGVITlJid3n0bEBKSzVyIH;mJFMvOiEQvF2= M4PSV|IyODhyNkK5
HeLa NWjwVHMzS3m2b4TvfIlkKEG|c3H5 MnnyO|IhcA>? NH3zbpNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2= NEXlfnYzOTB6ME[yPS=>
Sf21 MXPLbY5ie2ViQYPzZZk> NVqzRZllOyCq NX:5PVVPUW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0> NVnufmtbOjFyOEC2Nlk>
SKBR3 MVTDfZRwfG:6aXOgRZN{[Xl? MmrsO|IhcA>? MlqzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?= MlXFNlExQDB4Mkm=
SKOV3 MonHR5l1d3SxeHnjJGF{e2G7 NYL5XpBXPzJiaB?= NXnES3lKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi5{IN88US=> M2jw[lIyODhyNkK5
COR-L23 NI\ufYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNEDPxE1? Mnm1O|IhcA>? NVL3V3FpTE2VTx?= MoDiS2k2OD1zLkGg{txO NUXlcJNlOjFyOEC2OFc>
DU145 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO3NVAh|ryP M2rL[|czKGh? NGDNcYhFVVOR M4\1WmdKPTB;MT6wOUDPxE1? NEH0bJgzOTB6ME[0Oy=>
LoVo MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3KTHEyOCEQvF2= M4HsOVczKGh? NXPxXXRQTE2VTx?= MXvHTVUxRTFwNzFOwG0> M4\kN|IyODhyNkS3
MCR5-SV2 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC4WlZTOTBizszN NFW0emk4OiCq NUL3TXh2TE2VTx?= MWnHTVUxRTJwMTFOwG0> NX63SVNZOjFyOEC2OFc>
HCT116 MXnLbY5ie2ViQYPzZZk> M3XPVVMxKM7:TR?= MX6zNEBp NWH3UFgyTE2VTx?= MnTGTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?= NF3mNFgzOTB6ME[0Oy=>
HCT116 NV7M[YdxU2mwYYPlJGF{e2G7 MYSzNEDPxE1? MmGxN|AhcA>? M1fOO2ROW09? MVrJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizT|kh[WOndInsZZRqd25? MlrVNlExQDB4NEe=
U937 M3;oOmtqdmG|ZTDBd5NigQ>? MnvHOUDPxE1? MniyNlQhcA>? NV7vR5N{TE2VTx?= MULJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMQQ>? MW[yNVI6OjR7Mh?=
U937 MkfpT4lv[XOnIFHzd4F6 MlXsOUDPxE1? MoTNNlQhcA>? M2\4eGROW09? NIq0PY9KdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4Yh[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCCNMUi= MXmyNVI6OjR7Mh?=
U937 M1jn[WtqdmG|ZTDBd5NigQ>? MmXKOUDPxE1? MYOyOEBp Mkf1SG1UVw>? Mn\vTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJJBidi2jY3X0fYxifGWmIHjpd5RwdmViSESgcIV3\Wx? MXGyNVI6OjR7Mh?=
U937 MlrRT4lv[XOnIFHzd4F6 M1\5SlUh|ryP NGXaV24yPSCvaX6= MVLEUXNQ M1n2cmlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIHzleoVt MVmyNVI6OjR7Mh?=
A2780 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rSWlk3KGh? M17mcGROW09? Ml;GTWM2OD1zLk[yJO69VQ>? MoDlNlE3OzR2M{C=
COLO205 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe5OkBp NWi2PVZLTE2VTx?= NHm3b41KSzVyPUKuNVIh|ryP MYiyNVY{PDR|MB?=
Hep3B MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GzRlQ5KGh? NWD2VWw1TE2VTx?= MlTES2k2OD1zLkKxJO69VQ>? MX6yNVcyOjF2Nh?=
GM11272 NHfYblBHfW6ldHnvckBCe3OjeR?= NFHuTJIyODBibl2= NVqzZmt5PzJiaB?= NF\vS3dFVVOR NF\6[oRT\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O M1fjZVIyQDRyN{G2
CFBE41o MkPFT4lv[XOnIFHzd4F6 NVPLe2V{PSEQvF2= NFz3WVdFVVOR Mk[4SI94diC{ZXf1cIF1cW:wIH;mJGhFSUN5IHH0JFAvOiC2bzC1JJVO MVWyNVk5PDl3OB?=
CFBE41o MlvoSpVv[3Srb36gRZN{[Xl? NHrnclcyKM7:TR?= M4DNO|I1KGh? NYK3TpdJTE2VTx?= MWfS[ZN1d3KjdHnvckBw\iCFRmTSJIRmdHSjRkWwPEBufXSjboSgeJJi\m[rY3vpcochfG9iY3XscEB{fXKoYXPlJIF{KGeueXPv[o9zdXN? MoHRNlE6QDR7NUi=
DU145 NXLZdYdnU2mwYYPlJGF{e2G7 NVPiSHFZOi53IN88US=> NES4VnQzPCCq M1nVcGROW09? MYrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOXejZkGgdJJwfGWrbjDlfJBz\XO|aX;u Mkm0NlIzPjBzNk[=
DU145 MkfET4lv[XOnIFHzd4F6 MUC1JO69VQ>? NH\WfIQzPCCq MUDEUXNQ NV;jO5RGUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHjpd5RwdmViSESgZYNmfHmuYYTpc44> M{XFT|IzOjZyMU[2
DU145 NUP4XJR[U2mwYYPlJGF{e2G7 M375PFUh|ryP NWK2RVdXOjRiaB?= NUjje5V7TE2VTx?= NUHB[mNmUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHjpd5RwdmViSEOgbJlx\XKjY3X0fYxifGmxbh?= Mnq0NlIzPjBzNk[=
786-0 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLBbGI3NjJizszN MoHhO|IhcA>? NX36Vng5TE2VTx?= NFLDbGxIUTVyPUOuNkDPxE1? NEHlVI4zOjR|NU[2PS=>
A498 NGfuSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXDOk4zKM7:TR?= M{C1XFczKGh? MlrtSG1UVw>? MmfyS2k2OD1zLk[g{txO MorXNlI1OzV4Nkm=
A549/ATCC NHX5dFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULzcIVJPi5{IN88US=> MWS3NkBp NYL4XGUxTE2VTx?= NFrHPZhIUTVyPUGuOkDPxE1? MXeyNlQ{PTZ4OR?=
ACHN MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS2MlIh|ryP NYfMOGRUPzJiaB?= M2KwTmROW09? NFzsRlZIUTVyPUGuN{DPxE1? NYLCXIVyOjJ2M{W2Olk>
BT549 M3LLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmSxOk4zKM7:TR?= MVi3NkBp M4raPGROW09? NVzBe5VFT0l3ME2xMlMh|ryP MVeyNlQ{PTZ4OR?=
EKVX NVSxd4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn1U5NuPi5{IN88US=> NX;LU|VbPzJiaB?= MVvEUXNQ M3TXS2dKPTB;MT6zJO69VQ>? Mmi4NlI1OzV4Nkm=
HCT15 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi2MlIh|ryP NX\RZ3hPPzJiaB?= M3uzWGROW09? M3fnO2dKPTB;Mj61JO69VQ>? Mn\3NlI1OzV4Nkm=
HOP92 M3PIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHCdmY3NjJizszN MYW3NkBp NX:yOGI5TE2VTx?= M1f5cGdKPTB;NDFOwG0> NWfsO|A2OjJ2M{W2Olk>
IGROV1 M4CzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\2Ok4zKM7:TR?= M1rtTlczKGh? Mki3SG1UVw>? MkTLS2k2OD1zLkOg{txO MknlNlI1OzV4Nkm=
LOXIMVI NXPuVFBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfaZmdnPi5{IN88US=> NFPjVFM4OiCq MnfPSG1UVw>? MmjuS2k2OD1zIN88US=> NVvvXItEOjJ2M{W2Olk>
M14 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz3Ok4zKM7:TR?= NWSySm1sPzJiaB?= M4nZR2ROW09? MX7HTVUxRTFwMzFOwG0> Mlv5NlI1OzV4Nkm=
MALME-3M NVK5W4hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O0TlYvOiEQvF2= M33MZ|czKGh? MkPVSG1UVw>? NYfifpJzT0l3ME2wMlMzKM7:TR?= NEHu[nczOjR|NU[2PS=>
MCF10A MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe2MlIh|ryP MXy0PEBp MmPlSG1UVw>? MYnHTVUxRTlwNjFOwG0> NWLudIt6OjJ2M{W2Olk>
MDA-MB-435 NFzzXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL0Ok4zKM7:TR?= NXHqbYV4PzJiaB?= NITHU5pFVVOR NYjYSZNRT0l3ME2wMlUh|ryP MmPUNlI1OzV4Nkm=
MDA-MB-468 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KycFYvOiEQvF2= MnzYO|IhcA>? M2KyS2ROW09? MXnHTVUxRTBwNkOg{txO NE[4bJgzOjR|NU[2PS=>
MOLT4 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq2MlIh|ryP NWPF[VV4PzJiaB?= MXvEUXNQ M4izXWdKPTB;MD60JO69VQ>? NFf3[lYzOjR|NU[2PS=>
NCI-ADR-RES MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3[FYvOiEQvF2= M4jHXFczKGh? MlXFSG1UVw>? MXfHTVUxRTBwMU[g{txO MnjCNlI1OzV4Nkm=
NCI-H23 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjVOk4zKM7:TR?= M3TrZVczKGh? MoHMSG1UVw>? M1\VN2dKPTB;MTFOwG0> NEfI[WszOjR|NU[2PS=>
NCI-H322M MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOdVYvOiEQvF2= MmOwO|IhcA>? NHG5[IpFVVOR M1HiTGdKPTB;MD63PUDPxE1? MkToNlI1OzV4Nkm=
NCI-H460 NIqxcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV32XGZ2Pi5{IN88US=> NFTOPWc4OiCq NG\XOIJFVVOR M1fDeGdKPTB;MD63PUDPxE1? NXPofnpqOjJ2M{W2Olk>
NCI-H522 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DHTFYvOiEQvF2= MnjHO|IhcA>? MkHJSG1UVw>? MVPHTVUxRTBwNTFOwG0> NX;u[IxtOjJ2M{W2Olk>
OVCAR3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS2MlIh|ryP M1;pNlczKGh? NEjZNVNFVVOR MkTSS2k2OD1zLkOg{txO MnPDNlI1OzV4Nkm=
OVCAR4 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qzVFYvOiEQvF2= M33mbVczKGh? M3KwPGROW09? M4jQOWdKPTB;NDFOwG0> MoO3NlI1OzV4Nkm=
OVCAR5 NFniOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX22MlIh|ryP NVvxR|VsPzJiaB?= NGjweGNFVVOR Mnr4S2k2OD1yLke5JO69VQ>? MXKyNlQ{PTZ4OR?=
OVCAR8 M{D4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGyZYk3NjJizszN MkTMO|IhcA>? M4X3XWROW09? MYjHTVUxRTBwNTFOwG0> NXHFSJU6OjJ2M{W2Olk>
RXF393 NWTxfpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XXUFYvOiEQvF2= MWm3NkBp NGr3OpBFVVOR M{LLVWdKPTB;MT6zJO69VQ>? MlfFNlI1OzV4Nkm=
SF268 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn6VoRxPi5{IN88US=> NUH6OmdOPzJiaB?= MnPOSG1UVw>? MlnsS2k2OD1zLk[g{txO M4\SflIzPDN3Nk[5
SF295 M2nVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33pcFYvOiEQvF2= NF30fHQ4OiCq NX;pOVQ1TE2VTx?= MlT1S2k2OD1zLk[g{txO MVGyNlQ{PTZ4OR?=
SF539 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjhPYI3NjJizszN MlvZO|IhcA>? NEDnfZNFVVOR NGXSboFIUTVyPUKg{txO Mnu4NlI1OzV4Nkm=
SK-MEL-2 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\3b|YvOiEQvF2= M3njPFczKGh? NF7abnZFVVOR MUfHTVUxRTFwMzFOwG0> NXzBXXlyOjJ2M{W2Olk>
SK-MEL-28 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS1bJVjPi5{IN88US=> MXu3NkBp M3GzcmROW09? NHfVPIhIUTVyPUGg{txO NG\ke2MzOjR|NU[2PS=>
SK-MEL-5 NHTkS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnCd|VYPi5{IN88US=> NYHTeopjPzJiaB?= MnvBSG1UVw>? M1K3TGdKPTB;MD62N{DPxE1? NYPKc2toOjJ2M{W2Olk>
SKOV3 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK2MlIh|ryP MV63NkBp NFvoUWlFVVOR M4LtXWdKPTB;MTFOwG0> MUCyNlQ{PTZ4OR?=
SN12C MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKOk4zKM7:TR?= NIrmdVA4OiCq M2nKe2ROW09? MW\HTVUxRTJizszN M4fG[|IzPDN3Nk[5
SNB19 NFr5O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jjNFYvOiEQvF2= M4rySFczKGh? NF2xenVFVVOR NFLWW2xIUTVyPUCuOlMh|ryP MXGyNlQ{PTZ4OR?=
SNB75 M{Xyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLBOk4zKM7:TR?= M3nscFczKGh? M{PhPGROW09? NWC1fXA2T0l3ME2wMlc6KM7:TR?= MXWyNlQ{PTZ4OR?=
SR M2Xrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6wOk4zKM7:TR?= Mlr1O|IhcA>? NYLVWndrTE2VTx?= MlH4S2k2OD1yLkSg{txO NELhfnUzOjR|NU[2PS=>
T47D NWjO[GRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r2cVYvOiEQvF2= NEnYR444OiCq Mn22SG1UVw>? NIDRO3lIUTVyPUCuOUDPxE1? NFTQeYUzOjR|NU[2PS=>
TK10 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e1eFYvOiEQvF2= NV:4cFdGPzJiaB?= NUjOeGQ4TE2VTx?= M{n4WmdKPTB;MD62N{DPxE1? MlmzNlI1OzV4Nkm=
UACC257 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yz[FYvOiEQvF2= NVnOTZE2PzJiaB?= NXG3NHl1TE2VTx?= Mkm1S2k2OD1yLkWg{txO M3\VVVIzPDN3Nk[5
UACC62 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXTcZc3NjJizszN NH3oWnU4OiCq NWC0fY9YTE2VTx?= NED0OGNIUTVyPUCuOEDPxE1? NGXUbW8zOjR|NU[2PS=>
UO31 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHmXIQ3NjJizszN NHrJRXE4OiCq M{jyTWROW09? MonmS2k2OD1yLkWg{txO M1r1flIzPDN3Nk[5
Hep3B Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln5OFghcA>? MlLNSG1UVw>? NF\QRYJIUTVyPUCuOlkh|ryP M1jUTVIzPDN7OE[z
BE(2)-C NVvYR2J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp NHjBU3hFVVOR MkmzTWM4OD1{IN88US=> NILoUXkzOjl|MkOxOi=>
Bel7402 M1fjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTCdIhHPzJiaB?= Mo\QSG1UVw>? NIjGeHhIUTlyPUG3JO69VQ>? MWSyN|A3OTN5Nh?=
Bel7404 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXwXYZjPzJiaB?= MmfOSG1UVw>? M37nfWdKQTB;MUig{txO NILod48zOzB4MUO3Oi=>
BGC823 NGTqOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3NT2w4OiCq NG\ydGJFVVOR MlTLS2k6OD15LkWg{txO MVmyN|A3OTN5Nh?=
MGC803 NHHJNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXpcGNOPzJiaB?= M4fETmROW09? MVnHTVkxRTFyLkig{txO MVGyN|A3OTN5Nh?=
SGC7901 NHTIb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXNU2k4OiCq M2PhW2ROW09? NHv3fZFIUTlyPUmuOEDPxE1? M{PUZ|I{ODZzM{e2
SKHEP1 NFnobVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjpbIs4OiCq NVzsfYFoTE2VTx?= Moj2S2k6OD1zNzFOwG0> NG\0[VczOzB4MUO3Oi=>
SMMC7721 M3KyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH24[3A4OiCq Mn[2SG1UVw>? MVrHTVkxRTJyIN88US=> MVuyN|A3OTN5Nh?=
NUGC3 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNEDPxE1? NEDSOGpIUT1{Lkm0JO69VQ>? M4H0eFI{OTZ|M{Oy
A2780 CisR MUnLbY5ie2ViQYPzZZk> M3rkPVE5KGh? MW\Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNESg{txO NF;hOWUzOzJ3Mk[wNy=>
CAL27 sens MWrLbY5ie2ViQYPzZZk> NFLKPVMyQCCq MU\Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{[g{txO NVvEXmNXOjN{NUK2NFM>
CAL27 CisR NELEOmRMcW6jc3WgRZN{[Xl? M{fOUlE5KGh? M1;YW2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1? M1LOdlI{OjV{NkCz
KYSE-510 CisR NEX3N3hMcW6jc3WgRZN{[Xl? MYexPEBp MVHJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO NHLLVmQzOzJ3Mk[wNy=>
KYSE-510 sens M{DQbmtqdmG|ZTDBd5NigQ>? MmH3NVghcA>? NX7kWlVNUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlch|ryP NFPtdVAzOzJ3Mk[wNy=>
MDA-MB-231 sens MnrMT4lv[XOnIFHzd4F6 M{[xVFE5KGh? NWDhd|RvUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?= MWCyN|I2OjZyMx?=
MDA-MB-231 CisR NYDVcnk4U2mwYYPlJGF{e2G7 MV[xPEBp MofMTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>? MYmyN|I2OjZyMx?=
ES2 M4Hs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n6W|Q5KGh? NU\MSIhNTE2VTx?= NYCwZmY4UUN3ME2xNk44KM7:TR?= NGPtPGQzOzR7M{S0PS=>
MDA-MB-231 NXLPdG84U2mwYYPlJGF{e2G7 M2GyZ|ExKM7:TR?= MXqzNEBucW5? NETN[GxFVVOR NFzVcHBKdmirYnn0bY9vKG:oIFjERWMz[Q>? NHj1dG0zOzR7M{S0PS=>
MDA-MB-231 NWe3d3o4U2mwYYPlJGF{e2G7 M2f1SFEh|ryP NF7IS2szPCCq MX\EUXNQ NV;3PHBDUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=> NX\RZYs1OjN2OUO0OFk>
HS68 MYHDfZRwfG:6aXOgRZN{[Xl? Mn21NVAh|ryP MlHuO|IhcA>? MVHEUXNQ MoHBTWM2OD12Lk[g{txO M1jFXlI{PTdyNUSy
MEF M3z2SGN6fG:2b4jpZ{BCe3OjeR?= M1zKXVExKM7:TR?= MWW3NkBp NYTKdopxTE2VTx?= NUL1bGF1UUN3ME20MlQh|ryP MorFNlM2PzB3NEK=
BGC823 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLoZVJFVVOR MnPpS2k2OD1|LkC5JO69VQ>? MXSyN|YxOTdyNh?=
High5 M3\SfmtqdmG|ZTDBd5NigQ>? M3;YXFI1KGh? MmnoTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkB4cXSqIFnDOVAhd2ZiMD6wPUDPxE1? MlfCNlM3ODJ3MkO=
High5 Mlf3T4lv[XOnIFHzd4F6 Ml3nNlQhcA>? M2jkd2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR|Ehf2m2aDDJR|UxKG:oIECuNVIh|ryP MXOyN|YxOjV{Mx?=
High5 NGTXWG9McW6jc3WgRZN{[Xl? MYKyOEBp NYjQNG0xUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOyC5aYToJGlEPTBib3[gNE4yPyEQvF2= MVWyN|YxOjV{Mx?=
A549 NEfrcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfRXXM6TE2VTx?= Mm\CTWM2OD1zLkC3PUDPxE1? MXqyN|Y1PDJzMB?=
HCT116 M4n3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;LSG1UVw>? MXHJR|UxRTBwN{W3JO69VQ>? NHXHbIEzOzZ2NEKxNC=>
K562 NIfiTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPjdppFVVOR NEPoW4tKSzVyPUCuOlQ2KM7:TR?= NEL5[4kzOzZ2NEKxNC=>
GBC-SD MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH32TJM2KM7:TR?= MkXIO|IhcA>? NH3IZ2pFVVOR NHW5dpNKSzVyPUG0Mlgh|ryP NEXtS28zOzdyN{K2NC=>
HGC27 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW1JO69VQ>? NF;G[JM4OiCq MV\EUXNQ NVHOVW9SUUN3ME21MlQh|ryP Mm\QNlM4ODd{NkC=
HL60 MkTRT4lv[XOnIFHzd4F6 NFe5W4I2KM7:TR?= NUnHOG06OjRiaB?= M2nZXmROW09? MYPJcohq[mm2aX;uJI9nKEiGQVO= M4HnOVI{PzB5Mk[w
Vero NH6xW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHzZ2o4OiCq NH3DRnFFVVOR NF:2WFhKSzVyPUCuPUDPxE1? M3fiPVI{Pzh4NEWy
NCI60 NFzH[HhEgXSxdH;4bYMhSXO|YYm= M1G2bVQ5KGh? NYPHXoV3TE2VTx?= NGrMTHhIUT1yLkWzJO69VQ>? MoP3NlQxOTV|Mke=
SW620 NGfNRmpEgXSxdH;4bYMhSXO|YYm= Mn;nOFghcA>? MljsSG1UVw>? M1i1bmdKRTBwNUSg{txO MkDQNlQxOTV|Mke=
U251 NHX0SWpEgXSxdH;4bYMhSXO|YYm= NEnkXnM1QCCq Mn:3SG1UVw>? NXrvRoFVT0l;MT61N{DPxE1? NF\TTGszPDBzNUOyOy=>
KM12 NVrxenhRS3m2b4TvfIlkKEG|c3H5 M1vPRlQ5KGh? MXLEUXNQ MkH0S2k:OS56ODFOwG0> Mn72NlQxOTV|Mke=
Hs578T NYn3UWhPS3m2b4TvfIlkKEG|c3H5 NI\3Z201QCCq MkLESG1UVw>? M2rnW2dKRTRwOEOg{txO NEPNOlAzPDBzNUOyOy=>
MDA-MB-231 NXjtc5hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT4R3B7PDhiaB?= MVfJR|UxRTBwMU[g{txO NGPl[m0zPDB7NUCxOi=>
MCF7 M4XPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v1UFQ5KGh? NILSc2hIUT1yLkS1JO69VQ>? NVfve3ZiOjRzMUm1OVU>
MDA-MB-435 NGroN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j3cFQ5KGh? NVznflhQT0l;MD64PEDPxE1? NH:zWGszPDFzOUW1OS=>
AsPC1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfPWFc{OCEQvF2= NX;iSVlFPDhiaB?= NH7MdHBFVVOR NHLRSohKSzVyPUOuOlYh|ryP NUXaTJZQOjRzOEWzO|g>
Jurkat E6.1 MYPLbY5ie2ViQYPzZZk> Mnq3NkBp MoC3SG1UVw>? M1nFWWlvcGmkaYTpc44hd2ZiSFTBR|Qhf2m2aDDJR|UxKG:oIECuNFQh|ryP MVyyOFI3OTh4Mh?=
KG1 NUPCRlRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7GOFghcA>? NIC2R4FKSzVyPUGuNVUh|ryP NETmXZEzPDV{NUCwNy=>
HEL MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL0OFghcA>? MmC2SG1UVw>? MYHJR|UxRTBwNEmg{txO M4L2NFI1Pjl2MEW1
HSC3 MUXDfZRwfG:6aXOgRZN{[Xl? NILoXIgyOiCq NH7IV3dFVVOR MX;JR|UxRTBwN{Gg{txO NYrkTppzOjR5Nk[1OlA>
HT-29 NHL0c5lEgXSxdH;4bYMhSXO|YYm= NH;VOFUyOiCq M{DqOmROW09? M3\UOmlEPTB;MD63NkDPxE1? NWCzdlBxOjR5Nk[1OlA>
KB NIDMR4hEgXSxdH;4bYMhSXO|YYm= NIDSfIIyOiCq Mli0SG1UVw>? NIjoU3lKSzVyPUCuO|Uh|ryP NFPCb2wzPDd4NkW2NC=>
H460 MlmyR5l1d3SxeHnjJGF{e2G7 MYmxNkBp M33VSGROW09? MWTJR|UxRTBwOEKg{txO MXGyOFc3PjV4MB?=
MONE1 MkG4R5l1d3SxeHnjJGF{e2G7 MmLzNVIhcA>? NYK1RWdsTE2VTx?= MYTJR|UxRTFwMUig{txO M4rlT|I1PzZ4NU[w
MKN45 NYXNbY16S3m2b4TvfIlkKEG|c3H5 NGq5fIEyOiCq MYjEUXNQ MlS4TWM2OD1zLkK1JO69VQ>? MVKyOFc3PjV4MB?=
TSGH M2fWZmN6fG:2b4jpZ{BCe3OjeR?= MlfXNVIhcA>? M3LKXGROW09? Mn;rTWM2OD1{LkC5JO69VQ>? MlS0NlQ4PjZ3NkC=
HL60 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nkfVczKGh? M1HYU2ROW09? MWDHTVUxRTBwOUOg{txO Ml3oNlQ6ODB3MEC=
HEK293 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWflS5l{PzJiaB?= NGnnfGtFVVOR NFG1OZBIUTVyPUGzJO69VQ>? NVTGR2lMOjR7MEC1NFA>
Jurkat MmriR5l1d3SxeHnjJGF{e2G7 NWLaNFZyOTByIN88US=> MYG3NkBp M134cmdKPTB;MD65JO69VQ>? NEPCRoQzPDlyMEe0Ny=>
GM15850 MmrlT4lv[XOnIFHzd4F6 Mk[4Nk42KM7:TR?= M2iyR|k3KGh? NV;Hc4JjTE2VTx?= Mlr1[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l NUTPUpliOTZ7MkGzOlc>
GM15850 NETIXGNMcW6jc3WgRZN{[Xl? M1TIeVIvPSEQvF2= MmTvPVYhcA>? NFrUc|dFVVOR MYHkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= NFfQVHkyPjl{MUO2Oy=>
GM15850 MWnLbY5ie2ViQYPzZZk> MUKyMlUh|ryP MWC5OkBp MWDEUXNQ M2q2ZoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyOiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NVLFVFBrOTZ7MkGzOlc>
GM15850 MkXpT4lv[XOnIFHzd4F6 MWCyMlUh|ryP MlruPVYhcA>? NXz4VFVzTE2VTx?= Mn\3[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW= MnXGNVY6OjF|Nke=
GM15850 M4jVN2tqdmG|ZTDBd5NigQ>? NF74eZkzNjVizszN MVK5OkBp MlHTSG1UVw>? NX6xe|Fx\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDhiYXPleJlt[XSrb36gc4YhTliQIHflcoU> MXGxOlkzOTN4Nx?=
GM15850 MYLLbY5ie2ViQYPzZZk> NH7LT4szNjVizszN MVK5OkBp NGj2VGhFVVOR M17EbYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyPiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> MWOxOlkzOTN4Nx?=
GM15850 Ml\OSpVv[3Srb36gRZN{[Xl? M3XqS|Uh|ryP M{DpVlEzKGh? MWDEUXNQ M1r4[4hieyCwbzDl[oZm[3Rib36gSnhPKG2UTlGg[ZhxemW|c3nvci=> MX6xOlkzOTN4Nx?=
U937 M{f3bmtqdmG|ZTDBd5NigQ>? M4rtSFUh|ryP M33aOFI1KGh? MYDEUXNQ MUjoZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25? Mn;sNVc1PDd5NUC=
U937 MkmwT4lv[XOnIFHzd4F6 NGjic5UyKM7:TR?= MXGyOEBp MmP5SG1UVw>? NYDEV291cGG|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u MnvoNVc1PDd5NUC=
PANC1 Mn3FSpVv[3Srb36gRZN{[Xl? MYmxJO69VQ>? MXOyOEBp MoXB[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36= NXnNVnN1OTd3OEi3OFQ>
PANC1 NIrkZlFHfW6ldHnvckBCe3OjeR?= NH\6OYIyKM7:TR?= MV[0PEAhcA>? M3Tad4Rw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO|aX;u MYKxO|U5QDd2NB?=
Caco-2 MX7GeY5kfGmxbjDBd5NigQ>? NHmzTXc2KM7:TR?= MVqyOEBp M1vNO2ROW09? M2nVbYRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>? MYqyNFE1Ozh2MB?=
SCC4 M2foN2Z2dmO2aX;uJGF{e2G7 NUDNXVBLOSEQvF2= MYWxNEBucW5? MmjSSG1UVw>? NVztVXdZcGG|IH7vJIFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36= NYPMT2MzOjB2NUKyNlU>
A549 NHHHbGFHfW6ldHnvckBCe3OjeR?= M33QUVUh|ryP NXrEO|N7OyCq NETm[m5FVVOR Ml3C[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> MVOyNFg2PTJyOB?=
HCT116 NVvpeWtIU2mwYYPlJGF{e2G7 MYWwMlMh|ryP NYDsRWlXOzBiaB?= MUPEUXNQ MkGx[I9meyCwb4SgbY5pcWKrdDDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u MlXxNlExQDB4NEe=
HepG2 NVXjeW8xTnWwY4Tpc44hSXO|YYm= M4nNVFExKM7:TR?= M{D3Z|I1KGh? NGPGd2NFVVOR NETifmJld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZicEWz M4DLelIyPTR6NUiy
GM11272 MXPGeY5kfGmxbjDBd5NigQ>? MUSwMlEh|ryP MU[3NkBp MnjDSG1UVw>? NFv0b|hld2W|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO|aX;u NFyye2UzOTh2MEexOi=>
MDA-MB-231 Mn;YT4lv[XOnIFHzd4F6 NUnSeWFKOTBizszN NFXKOHA2KG2rbh?= NGHaXI1FVVOR Mmjm[I9meyCwb4SgbY5pcWKrdDDISGFEOmF? NHjY[lczOzR7M{S0PS=>
MDA-MB-231 MnjyT4lv[XOnIFHzd4F6 MX:xJO69VQ>? MmC3NlQhcA>? NVPWflNnTE2VTx?= NH\YVplld2W|IH7veEBqdmirYnn0JGhFSUN4IHHzd4V{e2WmIHHzJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iC2dXL1cIlv NYT1NGI5OjN2OUO0OFk>
K562 MYLLbY5ie2ViQYPzZZk> MUXkc4V{KG6xdDDpcohq[mm2IFjERWM> NIPQ[m8zOzV7MUGxNS=>
Jurkat MYHDfZRwfG:6aXOgRZN{[Xl? MXuyNEDPxE1? MYG3NkBp M1;WXWROW09? NU\sbHhmdm9iY4n0c5RwgGmlaYT5JIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9v MVGyOFMxPDN2OB?=
HCT116 NHO5N2VCeG:ydH;zbZMhSXO|YYm= MVWzJO69VQ>? MnixNlQhcA>? NF\5SJBFVVOR MWDkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKHB3MzDwdo91\WmwIHzleoVt NH;3TJkzPDd4NkW2NC=>
KASUMI-1 NF6zSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml31TWM2OD17OT6xO{BvVQ>? NUPvbpdsW0GQR1XS
KARPAS-45 NYT1eFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmy[IZPUUN3ME2xO|MvQDlibl2= NIK2N|RUSU6JRWK=
BHT-101 NXO3NINuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ2ND6xPEBvVQ>? M1TlcHNCVkeHUh?=
H9 M{jF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhO2lEPTB;MkW1MlA1KG6P MWHTRW5ITVJ?
PA-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfCOm83UUN3ME2yPFYvOjZibl2= MnzFV2FPT0WU
NEC8 M37xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jHO2lEPTB;Mki5MlM5KG6P NELxXmlUSU6JRWK=
MHH-PREB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW0TWM2OD1{OUSuOVMhdk1? MYPTRW5ITVJ?
NB7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HOOWlEPTB;M{S1Mlc1KG6P NHLOfZpUSU6JRWK=
A3-KAW NFezVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mzeWlEPTB;NECwMlU6KG6P NH;SSFVUSU6JRWK=
NB69 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTxZmtUUUN3ME20NVEvPzFibl2= NFrkfWlUSU6JRWK=
EoL-1-cell MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvoTWM2OD12NUSyOUBvVQ>? MWfTRW5ITVJ?
CHP-212 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nJ[WlEPTB;NEW3MlU{KG6P NHnqbpZUSU6JRWK=
C2BBe1 M3qzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17aVGlEPTB;NEeyMlE6KG6P NILKN|BUSU6JRWK=
697 M2rBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrReGxKSzVyPUS3N{41OSCwTR?= NHy4d|dUSU6JRWK=
BCPAP MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H3WmlEPTB;NUCxMlQzKG6P MXnTRW5ITVJ?
L-363 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj6RYtKSzVyPUWwN{4yKG6P NWPkeIx[W0GQR1XS
ES8 NYTzcIc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITYW4JKSzVyPUWyN{42OyCwTR?= NETlRlZUSU6JRWK=
BE-13 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r1N2lEPTB;NUK2Mlk3KG6P MUHTRW5ITVJ?
CTB-1 NHrvZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jufGlEPTB;NUO3MlkzKG6P MVHTRW5ITVJ?
HD-MY-Z MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTV|OD6xN{BvVQ>? NFnOe4dUSU6JRWK=
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTV2ND6yO{BvVQ>? MYfTRW5ITVJ?
NCI-H720 M1\TbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HwfmlEPTB;NU[wMlE5KG6P M37jc3NCVkeHUh?=
KY821 NE\TS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrDNJZmUUN3ME21OlMvOjVibl2= MYfTRW5ITVJ?
OVCAR-5 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe2d29KSzVyPUW3Ok4yOSCwTR?= MlSwV2FPT0WU
CTV-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GybWlEPTB;NUixMlU3KG6P NXLJSJlZW0GQR1XS
P12-ICHIKAWA MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTV7Nj61NUBvVQ>? MmK4V2FPT0WU
DB M2i3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L0O2lEPTB;NUm4MlU4KG6P M1XX[XNCVkeHUh?=
CHL-1 NW[yTndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GyWWlEPTB;NkSyMlA5KG6P MVLTRW5ITVJ?
A4-Fuk NVrQfGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\FdmlEPTB;NkS0MlkyKG6P MU\TRW5ITVJ?
MV-4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3OnhSUUN3ME22OVkvOSCwTR?= MVrTRW5ITVJ?
RPMI-8226 M4T3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7QcmRKSzVyPU[3PE4yQCCwTR?= NVvWPY1nW0GQR1XS
NB14 MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZ7Nj65OUBvVQ>? NWrHToN5W0GQR1XS
DOHH-2 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnSOGhPUUN3ME23NFYvPjhibl2= MoTOV2FPT0WU
D-423MG NH;WS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP4XI85UUN3ME23NFYvQDlibl2= Ml\sV2FPT0WU
D-283MED NXrJN3VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPmVmVoUUN3ME23NVQvOTRibl2= MVjTRW5ITVJ?
ES1 NYXxW2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzxTXZZUUN3ME23NlQvPCCwTR?= NWD0SWJSW0GQR1XS
GOTO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2POVWlEPTB;N{K5MlEzKG6P MX3TRW5ITVJ?
NCI-H209 NH7hWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTqfFB3UUN3ME23NlkvQSCwTR?= MoDmV2FPT0WU
MOLT-13 NUTzUItxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL3TWM2OD15M{iuPVghdk1? MoTSV2FPT0WU
ATN-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3VWllKSzVyPUe0NE4zQCCwTR?= MYjTRW5ITVJ?
DU-4475 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHXNXRKSzVyPUe1NU46OSCwTR?= NV3nNFluW0GQR1XS
NB10 M3P4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXYTWM2OD15NUGuPVIhdk1? NH\0[mNUSU6JRWK=
KG-1 NWPxcnBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7CbmlQUUN3ME23O|UvPDVibl2= MkfOV2FPT0WU
MOLT-4 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vTWM2OD15OEeuOFYhdk1? MXnTRW5ITVJ?
TE-1 M{[xZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTd7MT6xJI5O M1XyTnNCVkeHUh?=
SBC-1 M1HMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfFTWM2OD15OUOuPFQhdk1? MnqwV2FPT0WU
HEL M{PsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnJSYVKSzVyPUiwOk4xQCCwTR?= NGPIWnRUSU6JRWK=
SK-MEL-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRThyOT60OEBvVQ>? M{XCenNCVkeHUh?=
KU812 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjRbFVKSzVyPUixN{4yKG6P NHjVfVJUSU6JRWK=
RPMI-8866 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7HSFk3UUN3ME24NVMvPjdibl2= MojKV2FPT0WU
ALL-PO NWHtVFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfBTWM2OD16MUSuOlYhdk1? NWLBPHg5W0GQR1XS
LU-139 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTh{Mj64OkBvVQ>? M3rucnNCVkeHUh?=
RS4-11 NHvuUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfNcGJzUUN3ME24N|IvPDVibl2= MmfyV2FPT0WU
EW-18 NYjDcG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLwTWM2OD16M{KuPVYhdk1? NVKwcIFQW0GQR1XS
P30-OHK M4flNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz6TWM2OD16M{WuO{BvVQ>? MnTLV2FPT0WU
D-566MG M4\DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHWeGtCUUN3ME24N|gvPjJibl2= NGXaR4lUSU6JRWK=
HSC-4 NGnNZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ZXGlEPTB;OES2MlUyKG6P MmHvV2FPT0WU
QIMR-WIL NVP3ZZlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTh4Mj6wN{BvVQ>? M4qxd3NCVkeHUh?=
SW954 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTh4Mz6xOkBvVQ>? NXnIUoJFW0GQR1XS
HGC-27 NUT1TmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;2c3JKSzVyPUi3Nk4{PCCwTR?= MnSyV2FPT0WU
HH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqzTWM2OD16OUSuNVIhdk1? M4O0dHNCVkeHUh?=
KE-37 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L2bGlEPTB;OEm0MlYzKG6P Mom4V2FPT0WU
SK-N-DZ M2P3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlyMD60N{BvVQ>? MlnuV2FPT0WU
J-RT3-T3-5 NHrmTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD17MUCuOFkhdk1? M4jjRXNCVkeHUh?=
A427 NHvtV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO0TWM2OD17MkCuPFQhdk1? NVTEPGNpW0GQR1XS
ECC10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTl2NT64O{BvVQ>? NXfPOI9CW0GQR1XS
EW-1 M4PmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLsOo1xUUN3ME25OFcvOjZibl2= MmfkV2FPT0WU
MIA-PaCa-2 M3L2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HPTGlEPTB;OUS5MlEzKG6P NIDNWYdUSU6JRWK=
HCC2218 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH0TWM2OD17NUiuOFghdk1? MY\TRW5ITVJ?
HAL-01 M{HaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD17NkiuNFQhdk1? M3n4Z3NCVkeHUh?=
RD NI\qbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfQeI1KSzVyPUm3OE41PSCwTR?= NIToXohUSU6JRWK=
SK-N-AS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y5fGlEPTB;OUi4MlEhdk1? MkL3V2FPT0WU
ML-2 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7jSVBKSzVyPUGuNFA1ODdizszN NXr1b2dQW0GQR1XS
MEL-HO MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjxRWRKSzVyPUGuNFA2QDJizszN NG\WWolUSU6JRWK=
MS-1 NWfTTW9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXnOnBKSzVyPUGuNFA3OTdizszN NGSxb5FUSU6JRWK=
NCI-SNU-1 M2L2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfsO4N7UUN3ME2xMlAzOzNzIN88US=> M4DpOXNCVkeHUh?=
8505C MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrxb5VKSzVyPUGuNFI{OzFizszN NX7iZ5ZwW0GQR1XS
MN-60 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvPN2R7UUN3ME2xMlAzPjhizszN M1jCSHNCVkeHUh?=
SAS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfWN4FKSzVyPUGuNFQxQDFizszN NHK1O2RUSU6JRWK=
EFM-19 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;2NItEUUN3ME2xMlA1QDd7IN88US=> NG\h[|VUSU6JRWK=
Ca9-22 NVXJRZNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XzSmlEPTB;MT6wOVExPyEQvF2= MUTTRW5ITVJ?
NBsusSR NVHOfFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnrTWM2OD1zLkC1NVY3KM7:TR?= MlK2V2FPT0WU
NB13 NYXYRm1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLZVpVKSzVyPUGuNFU2ODFizszN M1vHOHNCVkeHUh?=
SF295 NEjK[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfWNZdKSzVyPUGuNFY3OjRizszN MoH1V2FPT0WU
U-2-OS NX:zOIVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvuTWM2OD1zLkC3PVEyKM7:TR?= MYnTRW5ITVJ?
NCI-H526 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLvTWM2OD1zLkC4NlkyKM7:TR?= NIK4TldUSU6JRWK=
KMOE-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwMEm0NlIh|ryP Mn[wV2FPT0WU
RCM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPyTWM2OD1zLkGyNVAzKM7:TR?= MXzTRW5ITVJ?
MC116 NYDZ[Is3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu3epoyUUN3ME2xMlE{PjJzIN88US=> NVPtN3NRW0GQR1XS
NCI-H1092 NVLMSnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSxc2FTUUN3ME2xMlE2PDB4IN88US=> MYHTRW5ITVJ?
EW-3 M2L2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMUeyNVIh|ryP NV7CVZlGW0GQR1XS
HCT-116 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmxTWM2OD1zLkG3O|Uh|ryP Ml;RV2FPT0WU
MC-IXC M3jpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\TTWM2OD1zLkG3PFgyKM7:TR?= NYDqVWdFW0GQR1XS
LB1047-RCC NVrtN|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDLPZlKSzVyPUGuNVg{OTJizszN M3fScHNCVkeHUh?=
VM-CUB-1 M1fFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O4PGlEPTB;MT6xPVExQCEQvF2= MYnTRW5ITVJ?
NB5 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZOZo4UUN3ME2xMlE6QDV4IN88US=> M2q2fXNCVkeHUh?=
SKG-IIIa MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PhZWlEPTB;MT6yN|Q3PCEQvF2= M2TnUHNCVkeHUh?=
HO-1-N-1 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwMkO4N|Uh|ryP MWfTRW5ITVJ?
EFO-27 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfM[m83UUN3ME2xMlI2ODR|IN88US=> NW\QRppKW0GQR1XS
MHH-NB-11 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe1VVdKSzVyPUGuNlg{OjlizszN NFXyfmlUSU6JRWK=
SW620 NEHKNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fPS2lEPTB;MT6yPVAyQCEQvF2= MWfTRW5ITVJ?
MOLT-16 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwMkm3PVch|ryP NYfYWVF2W0GQR1XS
NTERA-S-cl-D1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHJZ5pKSzVyPUGuN|E4PjFizszN M2XrR3NCVkeHUh?=
VA-ES-BJ NF\lNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwM{K0O|ch|ryP MoOwV2FPT0WU
HCC1419 NWLFTY55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnHSlFQUUN3ME2xMlM1ODJ5IN88US=> NUnaTmV[W0GQR1XS
NCI-H69 M4racmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm4RY9KSzVyPUGuN|QyOTJizszN MXzTRW5ITVJ?
DEL M{PyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjFWmdKSzVyPUGuN|UyPjJizszN MkC0V2FPT0WU
LXF-289 M{TvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0SVhKSzVyPUGuN|UzPCEQvF2= NXT6R3pKW0GQR1XS
EW-11 M1\NTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32xR2lEPTB;MT6zOlAzPiEQvF2= NV;IfG54W0GQR1XS
KP-4 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSyZ41KSzVyPUGuN|cxQDVizszN MmPEV2FPT0WU
NOS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;mT3dxUUN3ME2xMlQyOTl2IN88US=> MlHGV2FPT0WU
SK-NEP-1 NWXSb4VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLTTIxLUUN3ME2xMlQyPjl|IN88US=> NFzOT2pUSU6JRWK=
LAMA-84 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv5TWM2OD1zLkSzPVQ2KM7:TR?= NYHER5ZsW0GQR1XS
ES5 NF3zNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwNESzJO69VQ>? MlfkV2FPT0WU
HuO9 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNEWzOlIh|ryP M4rtTXNCVkeHUh?=
COLO-684 M2i5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWzTWM2OD1zLkS2NVE5KM7:TR?= M{\Se3NCVkeHUh?=
EW-24 NFzZXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fuSGlEPTB;MT60OlU{OSEQvF2= MlHQV2FPT0WU
BV-173 M1zjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\QTWM2OD1zLkS3NlkyKM7:TR?= M{XIZ3NCVkeHUh?=
NCI-H1770 NV;OZ5NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XI[2lEPTB;MT60PFU{PiEQvF2= NF\tSnBUSU6JRWK=
HuP-T4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInZTIxKSzVyPUGuOFk{KM7:TR?= NVPDOZBVW0GQR1XS
TYK-nu MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n5NGlEPTB;MT60PVg2OSEQvF2= MYTTRW5ITVJ?
YH-13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXPfII6UUN3ME2xMlQ6QDl2IN88US=> MlfzV2FPT0WU
H4 M2HGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrvU4NnUUN3ME2xMlUxQTF{IN88US=> M3fFcXNCVkeHUh?=
OVCAR-8 M2LPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTOWXNUUUN3ME2xMlU1PDd5IN88US=> MWLTRW5ITVJ?
NCI-H23 NFjBNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH63XlRKSzVyPUGuOVQ3PDVizszN MYHTRW5ITVJ?
ES7 M4TkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nKbGlEPTB;MT61OFc4OyEQvF2= MlzGV2FPT0WU
COR-L88 NEC3d5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTKUZNwUUN3ME2xMlU3PDJ2IN88US=> M3jsVnNCVkeHUh?=
TI-73 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf3UFMzUUN3ME2xMlU6ODZizszN NUfuOGF2W0GQR1XS
RT-112 NG\KTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLpVoJKSzVyPUGuOVkzQDRizszN MWjTRW5ITVJ?
HuO-3N1 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknWTWM2OD1zLkW5N|g2KM7:TR?= M4nIS3NCVkeHUh?=
HC-1 M17kRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwNUm4OlYh|ryP NXLGTlJCW0GQR1XS
HT55 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj3VYVlUUN3ME2xMlY2OTNzIN88US=> NXLyfGw4W0GQR1XS
IA-LM NVfmfHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;pNGNKSzVyPUGuOlkzPzhizszN MUTTRW5ITVJ?
EM-2 M3rI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjEcplIUUN3ME2xMlcxODF2IN88US=> NFrG[YRUSU6JRWK=
MHH-ES-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHZcldKSzVyPUGuO|A1OzVizszN NHqzZ3hUSU6JRWK=
CAL-27 NWf4W3RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwN{C2NlEh|ryP M3jrOHNCVkeHUh?=
COLO-800 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e1cGlEPTB;MT63NVE4QSEQvF2= Mn7HV2FPT0WU
HCE-T NUe4VIpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljETWM2OD1zLkexOUDPxE1? MXnTRW5ITVJ?
CAMA-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlziTWM2OD1zLkexPVcyKM7:TR?= NETQPVJUSU6JRWK=
LOXIMVI MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYVI1KSzVyPUGuO|IyOSEQvF2= MXPTRW5ITVJ?
NH-12 NUH2RY5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe2VJhDUUN3ME2xMlczPjlzIN88US=> NIi0cFJUSU6JRWK=
TCCSUP MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Xhe2lEPTB;MT63NlgzQSEQvF2= Mn7wV2FPT0WU
MDA-MB-361 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPVXYVKSzVyPUGuO|MyPTdizszN NH3ydY9USU6JRWK=
EW-16 NGDxS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjN[Ih1UUN3ME2xMlc1OTB5IN88US=> NX[xTlF5W0GQR1XS
SNU-423 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHmTWM2OD1zLke1PFI4KM7:TR?= NWfIfJBrW0GQR1XS
Daoy MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwN{[zNVkh|ryP NFLteJRUSU6JRWK=
ES4 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwN{i3OFEh|ryP MVXTRW5ITVJ?
PFSK-1 M3n6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH6bVV{UUN3ME2xMlgxOzdizszN NWjsUG1MW0GQR1XS
ES3 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPzTWM2OD1zLkiyOlgyKM7:TR?= NUmzS4dqW0GQR1XS
ONS-76 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3[FFKSzVyPUGuPFI5QTdizszN MX\TRW5ITVJ?
JVM-3 NXzOZ|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ycndKSzVyPUGuPFU1PTFizszN Mom0V2FPT0WU
OS-RC-2 NGTNbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LG[WlEPTB;MT64O|E2OSEQvF2= MXrTRW5ITVJ?
COLO-320-HSR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vwVGlEPTB;MT64PFE6PyEQvF2= MX;TRW5ITVJ?
HN MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TUN2lEPTB;MT64PFczPSEQvF2= M2jObHNCVkeHUh?=
HT NIW0cpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHxd2l{UUN3ME2xMlg5QTR5IN88US=> NXzWbIlZW0GQR1XS
LoVo MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTzU2hzUUN3ME2xMlg6QDFizszN NYXkd2xIW0GQR1XS
CGTH-W-1 NInaUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nyXmlEPTB;MT64PVk1PiEQvF2= MUnTRW5ITVJ?
NB6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S0OmlEPTB;MT65NVI6QCEQvF2= M1zoc3NCVkeHUh?=
EW-22 NF65d4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjvXHZKSzVyPUGuPVI5QDdizszN MXXTRW5ITVJ?
ES6 NWfFSFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnTcVVKSzVyPUGuPVM3OzFizszN MWXTRW5ITVJ?
SCC-15 M4C0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33r[WlEPTB;MT65N|gyQSEQvF2= MYLTRW5ITVJ?
HL-60 M3;H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r3NmlEPTB;MT65N|kxOiEQvF2= MoLFV2FPT0WU
human HOP-92 MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fjbWlEPTB;MT65OFA3PSEQvF2= MV\TRW5ITVJ?
SW626 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fvRmlEPTB;MT65OFg6QSEQvF2= MWrTRW5ITVJ?
HEC-1 NWLSZm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLmTWM2OD1zLkm1N|Yh|ryP MnjXV2FPT0WU
LB2241-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXhTWM2OD1zLkm4NlMyKM7:TR?= MWHTRW5ITVJ?
Ramos-2G6-4C10 NUG2NWJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHhbFNKSzVyPUGuPVk1QTNizszN MXXTRW5ITVJ?
A101D NIe4UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml33TWM2OD1{LkKwN|A{KM7:TR?= M4jEeHNCVkeHUh?=
NCI-H446 NWXVVnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwMES1PVkh|ryP MlPvV2FPT0WU
SBC-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwME[xOFch|ryP MULTRW5ITVJ?
HOS MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5SWlEPTB;Mj6wO|Y2OyEQvF2= MmnkV2FPT0WU
K5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\2TWM2OD1{LkC3PFEyKM7:TR?= MXPTRW5ITVJ?
HLE MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[5TWM2OD1{LkC4OVI6KM7:TR?= M4C4WXNCVkeHUh?=
HSC-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJwMUK4PVgh|ryP NY\0e3dmW0GQR1XS
LCLC-97TM1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7H[oZKSzVyPUKuNVQ2QDNizszN M3nSOXNCVkeHUh?=
DMS-273 NIWzZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\oTWM2OD1{LkG0PFM4KM7:TR?= NXjwN3ExW0GQR1XS
TE-8 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfIfHpKSzVyPUKuNVU4PjVizszN MW\TRW5ITVJ?
DSH1 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTGTWM2OD1{LkG2N|k5KM7:TR?= MWTTRW5ITVJ?
CAL-51 NETHRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u3N2lEPTB;Mj6xOlY6QSEQvF2= M3rFfHNCVkeHUh?=
IST-SL1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwMU[4OFQh|ryP NHTDSWVUSU6JRWK=
GCT MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HhUGlEPTB;Mj6xO|c4KM7:TR?= NUfWdYRbW0GQR1XS
SW948 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPueXVKSzVyPUKuNVg1PTZizszN M{H0W3NCVkeHUh?=
NOMO-1 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z4e2lEPTB;Mj6xPVMyPyEQvF2= MXTTRW5ITVJ?
C8166 M2PnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJwMkGzN|Qh|ryP M4XYSHNCVkeHUh?=
OC-314 Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvKWmc5UUN3ME2yMlI{OjV7IN88US=> MknCV2FPT0WU
CAL-39 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwMkO2NlYh|ryP M3OySnNCVkeHUh?=
MDA-MB-453 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwMkSyO|Uh|ryP M{HBZnNCVkeHUh?=
A673 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTpTWM2OD1{LkK1PFYzKM7:TR?= M1PpS3NCVkeHUh?=
HTC-C3 M3T0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHITlVKSzVyPUKuNlY5PSEQvF2= NVLMeG9CW0GQR1XS
NCI-H1666 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfaRXJKSzVyPUKuNlgyOTFizszN M3KzN3NCVkeHUh?=
PSN1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Sb5p2UUN3ME2yMlI5QTF|IN88US=> NFPUb3VUSU6JRWK=
GI-1 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrkSXJKSzVyPUKuN|A2PDNizszN Ml\IV2FPT0WU
HuH-7 NFvIXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\NVmlEPTB;Mj6zNFY{PyEQvF2= MXLTRW5ITVJ?
JAR NWDMTYJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D0XGlEPTB;Mj6zNVk5PyEQvF2= MU\TRW5ITVJ?
5637 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zKUWlEPTB;Mj6zNlEzQSEQvF2= MV3TRW5ITVJ?
GB-1 NIHuOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\JTWM2OD1{LkOyN|M2KM7:TR?= MVLTRW5ITVJ?
KP-N-YS M1v1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTxRXU6UUN3ME2yMlMzPjF3IN88US=> NE[ye29USU6JRWK=
OAW-42 NXzEVWRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXzTWM2OD1{LkOzOFE3KM7:TR?= NVfhUmNPW0GQR1XS
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzZooxUUN3ME2yMlM{QTB4IN88US=> MljkV2FPT0WU
RH-18 NEm5NItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXVTWM2OD1{LkO1NFIzKM7:TR?= NFruS2tUSU6JRWK=
NCI-H1155 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwM{[3NlUh|ryP NFjrZVNUSU6JRWK=
NB17 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwM{iyOFMh|ryP M132SXNCVkeHUh?=
NCI-H1437 NXrYSJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwNEG4O|Mh|ryP Mlq0V2FPT0WU
SN12C Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmzW3pKSzVyPUKuOFMzOTRizszN NXXlV|BDW0GQR1XS
HSC-3 NHzpe|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M162OmlEPTB;Mj60OFUxQSEQvF2= MXzTRW5ITVJ?
GAMG NG\GNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7MNYdKUUN3ME2yMlQ1PTZzIN88US=> Mm\EV2FPT0WU
HT-1080 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwNES4OlQh|ryP MVTTRW5ITVJ?
A549 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfpN2ZWUUN3ME2yMlQ1QDl|IN88US=> M4jDPXNCVkeHUh?=
KNS-62 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPoPWhKSzVyPUKuOFUxPjFizszN NVnuR2xjW0GQR1XS
YKG-1 NVLMNVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TBW2lEPTB;Mj60OVQ{PyEQvF2= MmHlV2FPT0WU
LU-134-A NWfv[5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwNEewNFgh|ryP MWDTRW5ITVJ?
FADU Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rNPGlEPTB;Mj60O|E3OiEQvF2= M1e5TnNCVkeHUh?=
TGBC11TKB NH3Zd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj0Wm86UUN3ME2yMlQ4OTd5IN88US=> NIPWSW9USU6JRWK=
HT-3 NInoeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS2TWM2OD1{LkS5OVM2KM7:TR?= M2DJNnNCVkeHUh?=
NCI-H2170 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLtTWM2OD1{LkWwOVQ6KM7:TR?= MULTRW5ITVJ?
Mo-T M13jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC2UZZwUUN3ME2yMlUxQTJ5IN88US=> NH\1fnBUSU6JRWK=
CCRF-CEM MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPJTWM2OD1{LkWzNFQ{KM7:TR?= NXzucod4W0GQR1XS
KU-19-19 M4LhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGyWo9DUUN3ME2yMlU{PTF|IN88US=> MkPsV2FPT0WU
NCI-H1048 M2K4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCwTWM2OD1{LkW1NFI2KM7:TR?= Mn3QV2FPT0WU
KOSC-2 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwNU[wO|Yh|ryP MYDTRW5ITVJ?
A431 M13yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS2TWM2OD1{LkW2N|M2KM7:TR?= M3G4bnNCVkeHUh?=
COR-L23 NH3ISZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\UfYM5UUN3ME2yMlU5PTZ4IN88US=> MXvTRW5ITVJ?
MKN28 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[xWWlEPTB;Mj61PVA{PyEQvF2= NF[4S4FUSU6JRWK=
22RV1 NEPuXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPhTWM2OD1{LkW5Nlc1KM7:TR?= M{T3Z3NCVkeHUh?=
ABC-1 NYPsbZZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[xTWM2OD1{Lk[wOFYh|ryP M1LjV3NCVkeHUh?=
NCI-H2126 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwNkC5PFQh|ryP NYS3PFhJW0GQR1XS
DoTc2-4510 NXjq[ZlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwNkKxPFUh|ryP M2TObnNCVkeHUh?=
SCC-4 M{f1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwNkOwNVIh|ryP MWfTRW5ITVJ?
NCI-H661 M33HW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOyfVlKSzVyPUKuOlQxQDVizszN MVfTRW5ITVJ?
RPMI-2650 M3\yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[4OGlEPTB;Mj62OFE1OyEQvF2= MoHHV2FPT0WU
NCI-H510A M3PwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjkTWM2OD1{Lk[0OFI3KM7:TR?= MoHpV2FPT0WU
BPH-1 NHjh[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwNkW4OUDPxE1? NF6yZ2hUSU6JRWK=
M14 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDyZYhKSzVyPUKuOlY6QTNizszN M4LwV3NCVkeHUh?=
G-402 M1yzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVznUoFOUUN3ME2yMlcxPDVzIN88US=> NV7hN3Z[W0GQR1XS
AsPC-1 NXzQTmp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7KfmZKSzVyPUKuO|EyPyEQvF2= MlexV2FPT0WU
NB12 NXjJepNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7OTWM2OD1{LkexO|Eh|ryP NFmwSYNUSU6JRWK=
SK-HEP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m2ZWlEPTB;Mj63OFM6OSEQvF2= NX23cpFUW0GQR1XS
U-266 NEjz[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwN{exNlEh|ryP M{jsTHNCVkeHUh?=
AM-38 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLtfXRTUUN3ME2yMlc4OzV3IN88US=> NYnVWmJyW0GQR1XS
PC-14 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjEXoVOUUN3ME2yMlgxPTFizszN NXP1U5kxW0GQR1XS
EGI-1 NV36VWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LoWGlEPTB;Mj64NVc1OyEQvF2= NF[5OGVUSU6JRWK=
LS-411N MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DGb2lEPTB;Mj64NlM{KM7:TR?= M1L3VXNCVkeHUh?=
BFTC-905 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKzUXNXUUN3ME2yMlg2PTJ|IN88US=> Mn\tV2FPT0WU
CaR-1 NX7ufXVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOxbmltUUN3ME2yMlg3KM7:TR?= MoXXV2FPT0WU
NCI-H292 NYfKSmRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjYc5FKSzVyPUKuPFY2QTZizszN NVXaO29rW0GQR1XS
8305C NEjKd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPBTWM2OD1{Lki2OlQ2KM7:TR?= MVvTRW5ITVJ?
SNU-449 NGWxeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ThNmlEPTB;Mj64PVE5OiEQvF2= M1XhO3NCVkeHUh?=
LCLC-103H MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HuR2lEPTB;Mj65NFQ{QCEQvF2= NYXxc3lEW0GQR1XS
SW1573 M{j3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JVGlEPTB;Mj65OlA5OiEQvF2= MXrTRW5ITVJ?
MLMA NELQbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLQSldKSzVyPUKuPVY4OTdizszN MUnTRW5ITVJ?
NCI-H1355 NInLOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjnTWM2OD1|LkCwO|k3KM7:TR?= NEHEbYlUSU6JRWK=
RMG-I MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfLTWM2OD1|LkCyOVkzKM7:TR?= Mof5V2FPT0WU
BB65-RCC M4mycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjEVXpKSzVyPUOuNFM{OTRizszN M1zKXHNCVkeHUh?=
PC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlviTWM2OD1|LkCzPFc1KM7:TR?= NEXudYpUSU6JRWK=
SF268 NI\idHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;5eJlKSzVyPUOuNFQ2OjNizszN M1fqbXNCVkeHUh?=
NCI-H810 NWPST3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;YeppHUUN3ME2zMlA1QDJ|IN88US=> Ml;1V2FPT0WU
MEG-01 NULHcJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrNUXhKSzVyPUOuNFYyPjRizszN Mo\0V2FPT0WU
SW13 NGL2[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF75doRKSzVyPUOuNFc5PDdizszN M1jNVHNCVkeHUh?=
RH-1 NIrEbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwMUCyO|gh|ryP MYDTRW5ITVJ?
GT3TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;uepFKSzVyPUOuNVEzQDNizszN MojNV2FPT0WU
TK10 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD1|LkGzO|I1KM7:TR?= MnPGV2FPT0WU
T-24 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D3SGlEPTB;Mz6xOVA4KM7:TR?= M3T2SHNCVkeHUh?=
A498 M3rTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnlTWM2OD1|LkKwPFcyKM7:TR?= NU\yWJVyW0GQR1XS
GR-ST MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPvbnpKSzVyPUOuNlIyOzlizszN M1P2[HNCVkeHUh?=
LB2518-MEL NWT5R3JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnVNIFKSzVyPUOuNlI{QThizszN M1y3TnNCVkeHUh?=
T47D M{LXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwMkO2Nlch|ryP NH\VeHJUSU6JRWK=
NCI-H1651 NX;2NIdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG3R2dFUUN3ME2zMlI1PjR2IN88US=> M4jOTXNCVkeHUh?=
EC-GI-10 NYjmV5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfUcId[UUN3ME2zMlI3OTV|IN88US=> NHy4OZNUSU6JRWK=
HT-29 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzUTWM2OD1|LkK2OlE1KM7:TR?= MYrTRW5ITVJ?
GI-ME-N MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLnTWM2OD1|LkK5OVEyKM7:TR?= MX;TRW5ITVJ?
SW756 NYX6[VlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzXTWM2OD1|LkK5OlI6KM7:TR?= M13meHNCVkeHUh?=
RKO MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zoXmlEPTB;Mz6zNFc2PyEQvF2= M3TPfXNCVkeHUh?=
NCI-H1563 NULmfpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4iydWlEPTB;Mz6zN|AyQCEQvF2= NUHuWFFFW0GQR1XS
DJM-1 NUjrT4NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;IUmlEPTB;Mz6zO|Y4PCEQvF2= MlfOV2FPT0WU
L-428 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETKN4ZKSzVyPUOuOFAxPDVizszN NVvpbldqW0GQR1XS
NCI-H2122 NVTJZ5l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwNEGzNVIh|ryP NG\0bHhUSU6JRWK=
Ca-Ski M1;5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jyXmlEPTB;Mz60OVQ{KM7:TR?= MX\TRW5ITVJ?
639-V MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jJdWlEPTB;Mz60OlA2PyEQvF2= NUjzOHNoW0GQR1XS
SW1116 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEezc5hKSzVyPUOuOFYzPjlizszN MnriV2FPT0WU
DMS-114 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnK[ZpKSzVyPUOuOFcxPjZizszN M3TkTXNCVkeHUh?=
MZ2-MEL NV\ESYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjhTHAxUUN3ME2zMlQ4PjhzIN88US=> NFrGTlRUSU6JRWK=
COLO-829 M2HkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwNUCwO|Mh|ryP MXTTRW5ITVJ?
J82 NVfLfYl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwNUC1O{DPxE1? M4f5fnNCVkeHUh?=
EW-13 M{DEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH3S|JKSzVyPUOuOVI2OSEQvF2= M3q0enNCVkeHUh?=
RXF393 NF3DeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTNwNUOyPVQh|ryP NX;pbpJLW0GQR1XS
CAL-62 NVL1VlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[0co9KSzVyPUOuOVQ2OTRizszN NXy3d3pIW0GQR1XS
OCUB-M M2fpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;XTJA5UUN3ME2zMlU1PjZ3IN88US=> Mle2V2FPT0WU
BT-474 NU[wV5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezeGtKSzVyPUOuOlM{OSEQvF2= MXXTRW5ITVJ?
KYSE-180 M3LVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XnbmlEPTB;Mz62N|M4OiEQvF2= M4PVPXNCVkeHUh?=
NCI-H650 M371bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn4PHhKSzVyPUOuOlQzQDdizszN MVPTRW5ITVJ?
Detroit562 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXieZRKSzVyPUOuOlUxOjJizszN M1\0cXNCVkeHUh?=
SW48 NH3nV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwNkW2OVch|ryP NYXDOY1TW0GQR1XS
KYSE-450 NYS3PItjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fFbWlEPTB;Mz62PFU5OiEQvF2= NWnqT5VuW0GQR1XS
KYSE-510 NEnWXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zQPWlEPTB;Mz63NlE5OSEQvF2= M2W4e3NCVkeHUh?=
GP5d NXGybos{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuxdIxqUUN3ME2zMlczQTVizszN NVryNodUW0GQR1XS
RPMI-7951 M1:0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D3PGlEPTB;Mz63OFczOyEQvF2= M2rSNXNCVkeHUh?=
Becker MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwN{WwNVIh|ryP M1T2WHNCVkeHUh?=
WM-115 NWnqcJZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\USY54UUN3ME2zMlc5OTl3IN88US=> NVqxNHhOW0GQR1XS
G-401 NFK1NpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLVTWM2OD1|Lke5NFg2KM7:TR?= M1vGO3NCVkeHUh?=
PANC-08-13 M4LWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvvV3FUUUN3ME2zMlc6PjB{IN88US=> MmnCV2FPT0WU
SW982 M13Efmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;6RXg1UUN3ME2zMlgxPTVzIN88US=> M4f2XXNCVkeHUh?=
D-263MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXGTWM2OD1|LkiyNFUyKM7:TR?= M1zOVnNCVkeHUh?=
KM-H2 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPRd3RjUUN3ME2zMlgzPjJ2IN88US=> MUnTRW5ITVJ?
SK-MEL-3 NXnyPIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG2Z|FiUUN3ME2zMlgzQDRzIN88US=> M4nSdHNCVkeHUh?=
NCI-H1581 NV\RUGZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTYWmdYUUN3ME2zMlg1PDh6IN88US=> Mo\EV2FPT0WU
LS-123 M1vFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXONHRiUUN3ME2zMlg4QTB7IN88US=> NFjjT5lUSU6JRWK=
CAKI-1 M1vkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX3RYlCUUN3ME2zMlg6ODV{IN88US=> M1rhUnNCVkeHUh?=
MEL-JUSO MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\vXoZJUUN3ME2zMlg6OTV|IN88US=> M2TBbHNCVkeHUh?=
HCE-4 NEn2enlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfwOmNiUUN3ME2zMlkyPjZ|IN88US=> Ml;OV2FPT0WU
TE-10 M4DCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNwOUKwNUDPxE1? NHXxR3RUSU6JRWK=
OVCAR-4 NGjOWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfhTWM2OD1|LkmyPFg6KM7:TR?= MYjTRW5ITVJ?
ETK-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPmR49zUUN3ME2zMlk1PjN3IN88US=> MnTQV2FPT0WU
A2780 NVvL[4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrOfWp3UUN3ME20MlA2QTZ4IN88US=> Mn7LV2FPT0WU
LU-65 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TGTGlEPTB;ND6wO|Y{OyEQvF2= NYHEc2V2W0GQR1XS
BHY M3nNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TMOmlEPTB;ND6xNlQ6PSEQvF2= MVHTRW5ITVJ?
COR-L105 NInqWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\We2F5UUN3ME20MlE{ODVzIN88US=> M4Ti[XNCVkeHUh?=
CAL-12T M2e1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwMUOxNFMh|ryP Mn\OV2FPT0WU
SCH NYXtSZF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRwMUW3OFMh|ryP M123T3NCVkeHUh?=
CW-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRwMUmwNFEh|ryP NHHZbpNUSU6JRWK=
HCC1806 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwMkCzNVIh|ryP NVPpWIRrW0GQR1XS
KP-N-YN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmx[oJQUUN3ME20MlIxQTJ5IN88US=> NHHVdZRUSU6JRWK=
T98G M4e0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\k[GlEPTB;ND6yNlE2PyEQvF2= NIrnPVZUSU6JRWK=
CAL-54 MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwMkKzPFEh|ryP MonWV2FPT0WU
CAL-33 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuxb2pKSzVyPUSuNlMxPjRizszN MYXTRW5ITVJ?
SNU-C2B NXrlfZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fhemlEPTB;ND6yOFc3QSEQvF2= NEOzWGVUSU6JRWK=
NUGC-3 M4K1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPyTWM2OD12LkK1OVA2KM7:TR?= M17MXnNCVkeHUh?=
DOK MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq3O4lnUUN3ME20MlI3PTl|IN88US=> MWfTRW5ITVJ?
MMAC-SF M33USGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTJV|hvUUN3ME20MlI3QDV7IN88US=> M4jSVHNCVkeHUh?=
KYSE-70 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TYfGlEPTB;ND6yPVM1KM7:TR?= Mo[4V2FPT0WU
A204 NELmTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\1TWM2OD12LkO1PFA{KM7:TR?= M1\5bXNCVkeHUh?=
SCC-25 NEPuOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T1ZWlEPTB;ND6zOVgyQSEQvF2= M{XEU3NCVkeHUh?=
EPLC-272H MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L3TGlEPTB;ND6zPFk2KM7:TR?= NH\HfmpUSU6JRWK=
CAL-120 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTEeppjUUN3ME20MlM5QTl{IN88US=> NVvGW5FNW0GQR1XS
LS-513 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rmWWlEPTB;ND60NlE6QCEQvF2= NFfhWYFUSU6JRWK=
CAPAN-1 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwNEKzPFIh|ryP NHLRSphUSU6JRWK=
ESS-1 NVy5eHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTRwNEK3NlQh|ryP NYrXPZczW0GQR1XS
GMS-10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwNEK4NVkh|ryP NYTUe3U5W0GQR1XS
NCI-N87 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwNUC4Olgh|ryP M2rENXNCVkeHUh?=
HMV-II NXWzdIt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zZ2lEPTB;ND61NVc{KM7:TR?= NGLWPYtUSU6JRWK=
COLO-741 NFqwcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwNUW5PVQh|ryP MVrTRW5ITVJ?
MKN45 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXXXo5nUUN3ME20MlU4PzN{IN88US=> MknmV2FPT0WU
OAW-28 NUHmc2tnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7YTWM2OD12LkW4N|k5KM7:TR?= MnjOV2FPT0WU
OCI-AML2 M2TEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vWRmlEPTB;ND62OVI{QCEQvF2= M172bHNCVkeHUh?=
MDA-MB-231 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvOGZKSzVyPUSuO|AzPDNizszN Ml\oV2FPT0WU
NCI-H1648 NHzPPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T2eWlEPTB;ND63NlI4OyEQvF2= NEX5fYpUSU6JRWK=
NCI-H1792 MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDCU4xKSzVyPUSuO|YyODdizszN M4\DeHNCVkeHUh?=
GCIY M4[0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD12Lke3OFI1KM7:TR?= M1\MOHNCVkeHUh?=
Hs-578-T NHK5UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnntTWM2OD12Lke3OlU2KM7:TR?= MnLxV2FPT0WU
SW962 M1LDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSweYc2UUN3ME20Mlc5ODFzIN88US=> M37wXXNCVkeHUh?=
NCI-H630 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC3bXlKSzVyPUSuO|gxQDFizszN MYPTRW5ITVJ?
786-0 NGS0bVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfaTWM2OD12Lke4O|c{KM7:TR?= M3XibXNCVkeHUh?=
FTC-133 MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC2TWM2OD12Lke5NlY{KM7:TR?= MoPSV2FPT0WU
BT-20 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr4N4VOUUN3ME20Mlc6PDJ7IN88US=> MmPvV2FPT0WU
Mewo NHHsT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRwOEG3OFch|ryP NHHIdndUSU6JRWK=
SW780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\OUlQ4UUN3ME20Mlg2PzZ4IN88US=> NUK5OJQ1W0GQR1XS
OE33 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwOEe3NVMh|ryP MmTlV2FPT0WU
HCC1569 NH;oUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHKVG1EUUN3ME20Mlg5PDV6IN88US=> NXrzUYpkW0GQR1XS
TE-6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLd2lEPTB;ND65N|k4PyEQvF2= NH\lOZVUSU6JRWK=
SK-N-FI MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vmTGlEPTB;ND65OFQzOSEQvF2= NH;sZoJUSU6JRWK=
PANC-03-27 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\GNGlEPTB;ND65PVk3OiEQvF2= NWThV2RvW0GQR1XS
MCF7 NE[1[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnwR5cyUUN3ME21MlAxPzN6IN88US=> NWDROYJ6W0GQR1XS
UACC-257 M2L1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLldlJKSzVyPUWuNFI5PDVizszN NFGzUFBUSU6JRWK=
SW1088 NH\O[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOzb4t4UUN3ME21MlAzQTR2IN88US=> M3zZe3NCVkeHUh?=
A704 NWTmW2lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nTeGlEPTB;NT6wN|A3KM7:TR?= Ml;1V2FPT0WU
A2058 NYDzfJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPWTWM2OD13LkC1PVA5KM7:TR?= NEPaVplUSU6JRWK=
Calu-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnIbFRKSzVyPUWuNFY1PTJizszN NIW5b3VUSU6JRWK=
RERF-LC-MS NWn6TlVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6wVlBxUUN3ME21MlA3QTB|IN88US=> M1XSc3NCVkeHUh?=
AU565 NVzwNHpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTVwMEm3NFIh|ryP NWXMN5Y6W0GQR1XS
DMS-79 NVnnU5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HydmlEPTB;NT6xN|g5OyEQvF2= M37xSnNCVkeHUh?=
DK-MG Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;JTWM2OD13LkG4OFM5KM7:TR?= MnHKV2FPT0WU
HuCCT1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v6cGlEPTB;NT6yN|g2PiEQvF2= M{L3[XNCVkeHUh?=
HT-144 M2Djd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HBRmlEPTB;NT6yOFk5PyEQvF2= NWfTbIJsW0GQR1XS
M059J MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjrTWM2OD13LkK1O|Yh|ryP M3XuOHNCVkeHUh?=
COLO-792 NUGwZ5lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm4No5KSzVyPUWuNlY{PTZizszN NXXnNWVQW0GQR1XS
SF539 M1T4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0bXlnUUN3ME21MlI3PjN{IN88US=> NGC1T5dUSU6JRWK=
SK-UT-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVwMke3OVEh|ryP NYHkdldFW0GQR1XS
NCI-H1703 NUTHcFNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT5fJdKSzVyPUWuN|U5OjZizszN M1TofnNCVkeHUh?=
SW837 NG[yeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrqe3M3UUN3ME21MlM4QDd6IN88US=> M3rj[HNCVkeHUh?=
U251 NIK1fWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzhTWM2OD13LkO5NFk3KM7:TR?= MYTTRW5ITVJ?
SW1710 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrZcmtKSzVyPUWuOFE2PTRizszN NXfYbY1nW0GQR1XS
NCI-H1299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\lUGlEPTB;NT60OlM{PSEQvF2= MXjTRW5ITVJ?
RVH-421 M3T5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SxPWlEPTB;NT60PVkxQCEQvF2= NIXMXpVUSU6JRWK=
UM-UC-3 NIP2PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\lSGlEPTB;NT62NlY2OSEQvF2= MYTTRW5ITVJ?
MDA-MB-175-VII NF:zRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnFTWM2OD13Lk[0NFQyKM7:TR?= Mn3oV2FPT0WU
KYSE-270 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCzPI1pUUN3ME21MlY3ODNzIN88US=> NVL3N412W0GQR1XS
COLO-668 NX34T4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnEcFBKSzVyPUWuO|E{OiEQvF2= MWHTRW5ITVJ?
LN-405 M3S0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi3NW9KSzVyPUWuO|MxQDVizszN MmH1V2FPT0WU
HT-1376 M2LpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HxZWlEPTB;NT63PFA2OiEQvF2= Ml;TV2FPT0WU
769-P MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHPb3JKSzVyPUWuPFY4OThizszN NGf2SXRUSU6JRWK=
HuP-T3 M1LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD13Lki4Olc4KM7:TR?= Mn6zV2FPT0WU
MDA-MB-415 NEDUWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPVNo1jUUN3ME21MlkzOTN7IN88US=> M3;VSHNCVkeHUh?=
MKN7 M1uxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHsSo5KSzVyPUWuPVg5KM7:TR?= M1nsZ3NCVkeHUh?=
KS-1 NInPbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTDbpFtUUN3ME21Mlk5QDN4IN88US=> NWrUWZJVW0GQR1XS
647-V MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\qbWIxUUN3ME21Mlk6OTR6IN88US=> MWDTRW5ITVJ?
COLO-679 NGq0U3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwMECyOVUh|ryP Mn3jV2FPT0WU
AN3-CA NYrZelVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZwMEO0OFEh|ryP MYLTRW5ITVJ?
C32 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M124UmlEPTB;Nj6xN|A{PCEQvF2= MUXTRW5ITVJ?
KM12 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P6XmlEPTB;Nj6yOFA6QSEQvF2= NWTzNJNHW0GQR1XS
KINGS-1 NV\4Vm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTZwMk[xOVIh|ryP Mo[5V2FPT0WU
KYSE-410 M4XKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KyWWlEPTB;Nj6zNFY1PSEQvF2= MUDTRW5ITVJ?
HPAF-II NUL1XpBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrGSphKSzVyPU[uN|U1QCEQvF2= MVzTRW5ITVJ?
LAN-6 NXnHNXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZwNEm2N|Eh|ryP MnyxV2FPT0WU
LU-99A NEfoNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLhWnNKSzVyPU[uOVU6QDlizszN NVzjU2hFW0GQR1XS
SJSA-1 NHjSOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKxbHk5UUN3ME22MlU3OzR5IN88US=> MWHTRW5ITVJ?
MSTO-211H NXLo[FdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTZwN{KyN|Mh|ryP MVnTRW5ITVJ?
SW900 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwN{[yNlEh|ryP NYCz[2V6W0GQR1XS
LNCaP-Clone-FGC NXW4XmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrHV5V[UUN3ME22MlgxPDB|IN88US=> M4Xjb3NCVkeHUh?=
OMC-1 NF\tWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrCSXoyUUN3ME22Mlg2PDB{IN88US=> MkfZV2FPT0WU
IST-MEL1 NXvJSGlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnDWos4UUN3ME22Mlg6PjZ7IN88US=> NIT2OHpUSU6JRWK=
TE-9 NFrBXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj6UXFnUUN3ME22Mlg6QDR5IN88US=> MYHTRW5ITVJ?
NCI-H2030 NYDMTnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lrd2lEPTB;Nj65NVIzPiEQvF2= NF3xPZZUSU6JRWK=
BFTC-909 M2jMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzibWFKSzVyPUeuNFA3PDFizszN NXvBOFcxW0GQR1XS
NCI-SNU-5 NWHqdYtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTDTWM2OD15LkCyNVU6KM7:TR?= NFvLZ45USU6JRWK=
TE-5 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zNb2lEPTB;Nz6wNlg5OSEQvF2= NH\zXVhUSU6JRWK=
SK-MES-1 NVjsV5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTdwMEW0Nlch|ryP Mo\WV2FPT0WU
SHP-77 M4D5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4frcGlEPTB;Nz6xN|k2OiEQvF2= M4XP[HNCVkeHUh?=
NCI-H1623 MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrqTWM2OD15LkG0NFczKM7:TR?= NI\hfmRUSU6JRWK=
TE-11 NI\sdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\BTWM2OD15LkG1NVg1KM7:TR?= NFjlfJhUSU6JRWK=
EKVX NG\0S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrHTWM2OD15LkG5NlY4KM7:TR?= MkDYV2FPT0WU
OVCAR-3 M13yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\nZ2pKSzVyPUeuNlEyOzNizszN MUPTRW5ITVJ?
C3A M1;kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnTTGJKSzVyPUeuN|Q2OiEQvF2= M17xO3NCVkeHUh?=
CFPAC-1 NUTXUIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO2TWM2OD15LkO2NlIzKM7:TR?= NWfIWXJ6W0GQR1XS
MG-63 NGjSSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTdwNEG4OFkh|ryP NU\3T3BbW0GQR1XS
KYSE-140 M2TTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjZWoFQUUN3ME23MlQ1ODZzIN88US=> NH;2doxUSU6JRWK=
MPP-89 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDLNmxKSzVyPUeuOVk4OjlizszN M{DJfHNCVkeHUh?=
COLO-824 M1nGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTDb2NKSzVyPUeuO|I5PjNizszN Mli5V2FPT0WU
SiHa MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Ie2xKSzVyPUeuPFM4ODdizszN NGiyVG9USU6JRWK=
SNU-387 NYPJOGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwOEWzOFch|ryP M13NbHNCVkeHUh?=
A172 M4r6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPYXFk6UUN3ME23Mlg3OTd{IN88US=> MWTTRW5ITVJ?
COLO-680N NFLiOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3VmlEPTB;Nz65NVc{KM7:TR?= NVzG[WVnW0GQR1XS
HCC1395 NYXTdYtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlruTWM2OD16LkC1OFUzKM7:TR?= M{XzWHNCVkeHUh?=
NCI-H28 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRThwMEW5OlMh|ryP M2\iUHNCVkeHUh?=
LC-2-ad Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvlfXBKSzVyPUiuNlE6OzdizszN M4K1bHNCVkeHUh?=
S-117 NF65SHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV76b|JPUUN3ME24MlI2OzV|IN88US=> MmrOV2FPT0WU
NCI-H1838 M{HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD6[FhIUUN3ME24MlI2PzhzIN88US=> NFPrfFNUSU6JRWK=
PANC-10-05 NGryVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTXbndGUUN3ME24MlM4ODR5IN88US=> MX7TRW5ITVJ?
KALS-1 NXrpbXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPidnJ6UUN3ME24MlUxQTJ6IN88US=> NXHJZnZiW0GQR1XS
LS-1034 M33yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRThwNUe0N|ch|ryP M2DxRnNCVkeHUh?=
TGBC1TKB NUi5eFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17QXWlEPTB;OD63N|U{PSEQvF2= MnP3V2FPT0WU
OE19 M4jRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;CfYlQUUN3ME24Mlc3OjZ{IN88US=> M{jVbnNCVkeHUh?=
D-502MG M2\TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRThwN{[5PVQh|ryP M1jnVHNCVkeHUh?=
JEG-3 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnobFRKSzVyPUiuO|g3OThizszN NV\BUYZ[W0GQR1XS
DBTRG-05MG NWPZWW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXPdYxKSzVyPUiuPFc2PjVizszN MoG4V2FPT0WU
ME-180 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnpW3RKSzVyPUmuNFY4OjVizszN NX:5U41uW0GQR1XS
NCI-H1573 NF20O|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnhVGFKSzVyPUmuNVA2OzJizszN NVnKfop3W0GQR1XS
HCC2998 M{DtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPKPWhKSzVyPUmuNVM3QDFizszN NYXj[JhZW0GQR1XS
ACHN M17jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjzNlYxUUN3ME25MlI1QTd3IN88US=> M3PaR3NCVkeHUh?=
D-392MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnXd3JwUUN3ME25MlI2PzF3IN88US=> MYrTRW5ITVJ?
no-11 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETKNZRKSzVyPUmuNlYxOjhizszN M2jlZ3NCVkeHUh?=
KLE M3TxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK3TWM2OD17LkOyNlMzKM7:TR?= MWDTRW5ITVJ?
Calu-6 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonuTWM2OD17LkO3OVI5KM7:TR?= NEnxdY9USU6JRWK=
LB831-BLC NG\rc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTlwNEWxO|Eh|ryP MkH3V2FPT0WU
SW684 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTlwNE[xNVYh|ryP MV;TRW5ITVJ?
SH-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLoTpBKSzVyPUmuOFk{PjRizszN MnXwV2FPT0WU
IST-MES1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTlwNUG2OFQh|ryP NUL3ZoZ2W0GQR1XS
Saos-2 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj4TWM2OD17LkWyNVk2KM7:TR?= M4XKeXNCVkeHUh?=
NCI-H2087 NE\RdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT5TWM2OD17Lk[3N|UzKM7:TR?= MYfTRW5ITVJ?
SCC-9 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37U[GlEPTB;OT63NVgyPiEQvF2= MXvTRW5ITVJ?
MFE-280 NIXQcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTlwN{K3PFUh|ryP NYrXb5ZmW0GQR1XS
BEN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTnTWM2OD17LkiyNVU6KM7:TR?= MkjQV2FPT0WU
CP50-MEL-B M4\0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGxWWFKSzVyPUmuPVI1OzJizszN NV\n[2JQW0GQR1XS
SK-MEL-28 NHrYfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTzTY9KSzVyPUGwMlAyQTNizszN NXfNVJZNW0GQR1XS
NCI-H2452 NFfBdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXWTWM2OD1zMD6xOkDPxE1? NYLR[3JFW0GQR1XS
NCI-H1395 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzETWM2OD1zMD6xO|gh|ryP MVzTRW5ITVJ?
NCI-H2052 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T5WmlEPTB;MUCuNVg5OiEQvF2= MYfTRW5ITVJ?
A375 NFG2eHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf5TWM2OD1zMD6yOFUzKM7:TR?= MmG2V2FPT0WU
HCC38 NH:xXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfCTWM2OD1zMD6zNlIh|ryP NXvlU5VRW0GQR1XS
LK-2 M3PWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJO4VsUUN3ME2xNE41OjB6IN88US=> M2\h[HNCVkeHUh?=
SF126 NX3MTVdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjNTWM2OD1zMD60O|I4KM7:TR?= M3\TWXNCVkeHUh?=
SK-MEL-1 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36wbGlEPTB;MUCuO|g{QCEQvF2= NYDmVWc{W0GQR1XS
ACN M2HuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\kdnVRUUN3ME2xNE45Pjd7IN88US=> MXfTRW5ITVJ?
BB30-HNC MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qzU2lEPTB;MUCuPFcyOSEQvF2= MUPTRW5ITVJ?
NCI-H747 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\1NWlEPTB;MUCuPFc1PiEQvF2= NWfCc3BrW0GQR1XS
KYSE-150 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFzLkCzPFch|ryP NIO2OIJUSU6JRWK=
D-247MG NYjL[ohIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf4TWM2OD1zMT6xNFA6KM7:TR?= MmGxV2FPT0WU
BxPC-3 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLTdXFKSzVyPUGxMlM4PDdizszN MnHnV2FPT0WU
SK-MEL-30 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\wTWM2OD1zMT60NFc6KM7:TR?= NUfHNlJuW0GQR1XS
CAS-1 NVHuNJpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO0[XRKSzVyPUGxMlQyODlizszN NH\ESFdUSU6JRWK=
no-10 NUXRfnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX23SpF4UUN3ME2xNk4yOjF5IN88US=> MWDTRW5ITVJ?
NCI-H2405 M1rTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjJOmlFUUN3ME2xNk4zODN4IN88US=> M{TiN3NCVkeHUh?=
KGN NVrnOWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLsRVJKSzVyPUGyMlI6ODFizszN Mk\uV2FPT0WU
BB49-HNC NWjLWI8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofNTWM2OD1zMj6zPVU3KM7:TR?= NWjHdWQzW0GQR1XS
NCI-H1693 NFzkVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DaVGlEPTB;MUKuOVgyPiEQvF2= NFHGRVZUSU6JRWK=
RO82-W-1 MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELNb3hKSzVyPUGzMlA3PDlizszN MoXCV2FPT0WU
CAL-85-1 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrST3JKSzVyPUGzMlQ{QTlizszN NIfQTW9USU6JRWK=
H-EMC-SS NFWxdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\o[WlEPTB;MUOuPVExPCEQvF2= Mk\xV2FPT0WU
SW1783 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzxTWM2OD1zND6yN|kyKM7:TR?= NUXhcXZvW0GQR1XS
LB771-HNC MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHVTWM2OD1zND60NVkh|ryP MXLTRW5ITVJ?
HCC70 NGm1dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XybGlEPTB;MUSuOFI{OyEQvF2= MXrTRW5ITVJ?
KNS-81-FD NFmwSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrtOINjUUN3ME2xOE44ODR3IN88US=> Mn7oV2FPT0WU
KYSE-520 NVnMS4hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHxTlRNUUN3ME2xOE46OjdizszN M1HEZ3NCVkeHUh?=
TGBC24TKB M2\0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jzSWlEPTB;MUSuPVU{QSEQvF2= NUH2NYJGW0GQR1XS
SNB75 M37hbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYntUGVkUUN3ME2xOU4xPzJ7IN88US=> M1O1dHNCVkeHUh?=
SW872 NHj1W2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzeINKSzVyPUG1MlIzOThizszN MVHTRW5ITVJ?
U031 NGDXVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TORmlEPTB;MUWuPFAzQCEQvF2= NYnQ[IpmW0GQR1XS
ChaGo-K-1 M3S3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF3LkizOVkh|ryP Ml\2V2FPT0WU
NCI-H441 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF4LkCwN|kh|ryP NYm2[XdxW0GQR1XS
TE-12 NYLnZlJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPieXpKUUN3ME2xOk4yQDd|IN88US=> MXHTRW5ITVJ?
NCI-H1755 NVzSZWxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonFTWM2OD1zNj61O|Mh|ryP NE\JU5pUSU6JRWK=
KNS-42 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\tOZFKSzVyPUG2MlY2QDlizszN NVnacZlVW0GQR1XS
SK-PN-DW NEi5Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF5LkSyNFEh|ryP M3HzO3NCVkeHUh?=
NCI-H226 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF5LkmzOFUh|ryP MYnTRW5ITVJ?
K-562 M2PzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOxU4I2UUN3ME2xPE43OzF5IN88US=> MUTTRW5ITVJ?
A388 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF7LkCzNFMh|ryP MmOxV2FPT0WU
ZR-75-30 NEn0W45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzsXGp5UUN3ME2xPU4xQTZ6IN88US=> MnXQV2FPT0WU
LU-135 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W0N2lEPTB;MUmuNlY{PiEQvF2= NHjB[VlUSU6JRWK=
NCI-H2029 M1LTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlUWpKSzVyPUG5MlYxOjFizszN MUTTRW5ITVJ?
HT-1197 M3vOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDrW4l4UUN3ME2xPU46OjJ5IN88US=> M2fDVnNCVkeHUh?=
IGR-1 M1H0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJyLkOxNVch|ryP MoLFV2FPT0WU
U-87-MG Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXlSmVKSzVyPUKwMlY1OTNizszN M3r4TnNCVkeHUh?=
NCI-H1304 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJyLke1NFEh|ryP M3:2[XNCVkeHUh?=
RCC10RGB M2rMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJzLkK4Nlkh|ryP MoXuV2FPT0WU
NCI-H520 NEPLWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ{Lke2NVEh|ryP MVrTRW5ITVJ?
SK-LU-1 M1W2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ|LkC3NVgh|ryP NYDsbJNrW0GQR1XS
UACC-893 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ|LkGwN|gh|ryP NVnjc2x5W0GQR1XS
NCI-H2347 M3nUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ|LkK2O|Qh|ryP NXjEXpc1W0GQR1XS
U-118-MG NUi5UGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPnOlJKSzVyPUKzMlczOTdizszN MWPTRW5ITVJ?
NCI-H596 NEfFNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjwWI5KSzVyPUKzMlkxPTVizszN NWfmfJFMW0GQR1XS
MZ1-PC M2q5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPYXZZkUUN3ME2yOE43PzV7IN88US=> MlfuV2FPT0WU
SW1417 NWr1OVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr5TWM2OD1{NT6yOFk5KM7:TR?= Moj5V2FPT0WU
NCI-H82 M3K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIS|RKSzVyPUK2MlQzQDhizszN NInHbXNUSU6JRWK=
COLO-678 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\5Z|F1UUN3ME2yO{41QTF7IN88US=> MlTHV2FPT0WU
KURAMOCHI Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[3TWM2OD1{OD6xNlYh|ryP NGnCbJpUSU6JRWK=
NCI-H1650 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW1TWM2OD1|MD6xPVI1KM7:TR?= NXWzR29UW0GQR1XS
HCC1954 NGfZcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMTWM2OD1|MT6zOlY3KM7:TR?= MUTTRW5ITVJ?
GAK NFPIcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ewb2lEPTB;M{KuNlYyPiEQvF2= MYjTRW5ITVJ?
YAPC NXW4cJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXrNpM2UUN3ME2zN{44PjR6IN88US=> MnzyV2FPT0WU
NCI-H2228 NVnqVIp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD0PW5KSzVyPUO0MlM3ODVizszN NYTj[G1SW0GQR1XS
VMRC-RCZ NYLO[GJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvkW5JKSzVyPUO2MlMxOjJizszN Mk[2V2FPT0WU
NMC-G1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nybGlEPTB;M{euNFUzQSEQvF2= M1XoRXNCVkeHUh?=
D-336MG NIeyelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD2WXN6UUN3ME20NU45PDR{IN88US=> M1O4bXNCVkeHUh?=
UACC-62 NYPYWVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR{LkW1NFUh|ryP NHHMSYZUSU6JRWK=
C-33-A M4HpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nZemlEPTB;NEWuN|I2PiEQvF2= MWPTRW5ITVJ?
HCC1937 NFXMTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiNoJKSzVyPUS3MlE6PThizszN NIPV[FBUSU6JRWK=
HDLM-2 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K0ZWlEPTB;NEeuNlI5PyEQvF2= M3fNXXNCVkeHUh?=
NCI-H727 NGTZcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHhWFI4UUN3ME20O{4zPDVzIN88US=> MnLHV2FPT0WU
NY MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTR7LkO5NFgh|ryP M4Ppc3NCVkeHUh?=
NCI-H2291 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR7LkizNFEh|ryP M3TqPHNCVkeHUh?=

... Click to View More Cell Line Experimental Data
In vivo Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]

Protocol

Kinase Assay:

[1]
+ Expand

Immunoprecipitation-HDAC assays:

The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research:

[2]
+ Expand
  • Cell lines: LNCaP, PC-3, and TSU-Pr1
  • Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM
  • Incubation Time: 1, 2, 3 and 4 days
  • Method:

    Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
  • Formulation: Dissolved in DMSO
  • Dosages: ~100 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (196.74 mM)
Ethanol 3 mg/mL (11.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 264.3
Formula

C14H20N2O3
CAS No. 149647-78-9
Storage powder
in solvent
Synonyms SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center July 2019 Early Phase 1
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center July 2019 Early Phase 1
NCT03843528 Not yet recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes|Mixed Phenotype Acute Leukemia|Juvenile Myelomonocytic Leukemia Johns Hopkins All Children''s Hospital May 1 2019 Phase 1
NCT03843528 Not yet recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes|Mixed Phenotype Acute Leukemia|Juvenile Myelomonocytic Leukemia Johns Hopkins All Children''s Hospital May 1 2019 Phase 1
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System April 1 2019 Phase 1
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System April 1 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommendation about reconstitution of the compound for in vivo animal study?

  • Answer:

    We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

selleck catalog

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

  • LMK-235 New

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603 New

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • Domatinostat (4SC-202) New

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Tags: buy Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) supplier | purchase Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) cost | Vorinostat (SAHA, MK0683) manufacturer | order Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID